Anonymity in Attribute-Based Group Signatures

Bhumika K. Patel,D. Jinwala

DOI: https://doi.org/10.1007/978-3-642-29280-4_58

2011-12-16

Abstract:

What problem does this paper attempt to address?

Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy

Oliver Schwartz,Katharina Vill,Michelle Pfaffenlehner,Max Behrens,Claudia Weiß,Jessika Johannsen,Johannes Friese,Andreas Hahn,Andreas Ziegler,Sabine Illsinger,Martin Smitka,Arpad von Moers,Heike Kölbel,Gudrun Schreiber,Nadja Kaiser,Ekkehard Wilichowski,Marina Flotats-Bastardas,Ralf A. Husain,Matthias Baumann,Cornelia Köhler,Regina Trollmann,Annette Schwerin-Nagel,Astrid Eisenkölbl,Mareike Schimmel,Martin Fleger,Birgit Kauffmann,Gert Wiegand,Manuela Baumgartner,Christian Rauscher,Sebahattin Cirak,Dieter Gläser,Günther Bernert,Tim Hagenacker,Susanne Goldbach,Kristina Probst-Schendzielorz,Hanns Lochmüller,Wolfgang Müller-Felber,Ulrike Schara-Schmidt,Maggie C. Walter,Janbernd Kirschner,Astrid Pechmann,Petra Baum,Moritz Metelmann,Fiona Zeiner,Wolfgang Löscher,Veronika Pilshofer,Kathrin Mörtlbauer,Elke Pernegger,Anna Elmecker,Tanja Neimair,Verena Angermair,Mika Rappold,Alexandra Ille,Magdalena Gosk - Tomek,Anna Wiesenhofer,Katia Vettori,Anna Hüpper,Theresa Stadler,Astrid Bertsche,Josefine Pauschek,Markus Blankenburg,Christof Reihle,Michael Schroth,Sarah Braun,Eva-Maria Wendel,Julia Haverkamp,Daniela Banholzer,Annette Karolin Homma,Jonas Denecke,Joenna Driemeyer,Deike Weiss,Paula-Sophie Steffens,Jila Taherpour,Marcus Deschauer,Paul Lingor,Luisa Semmler,Gerrit Machetanz,Matthias Eckenweiler,Bettina Henzi,Cornelia Müller,Thorsten Langer,Sabine Wider,Juliane Hug,Sabine Stein,Sibylle Vogt,Katharina Dörnbrack,Christina Saier,Adrian Tassoni,Franziska Wenzel,Tim Kampowski,Axel Gebert,Elisabeth Steiner,Manuel Pühringer,Sandra Baumann,Andrea Dall,Christina Bant,Tabea Reinhardt,Michael Zemlin,Sabine Hettrich,Dorothea Holzwarth,Stephanie Geitmann,Gabriel Dworschak,Franziska Busch,Ute Baur,Marion Richmann,Tobias Geis,Wolfgang Wittmann,Klaus Goldhahn,Manuela Theophil,Arpad von Moers,Katharina Müller-Kaempffer,Daniela Zeisler,Kathrin Bühner,Sylke Nicolai,Martin Groß,Stefan Kappel,René Günther,Maren Freigang,Hanna Sophie Lapp,Isabelle Dittes,Maria Wessel,Benjamin Stolte,Svenja Brakemeier,Andreas Thimm,Jaqueline Lipka,Melina Schlag,Kyriakos Martakis,Tascha Gehrke,Lisa Quinten,Andrea Hackemer,Lena Ruß,Omar Atta,Annina Lang,Eckard Hamelmann,Georg Classen,Klearchos Ntemiris,Kristina Albers,Loreen Plugge,Veronka Horber,Doris Roland-Schäfer,Andrea Bevot,Eva Jansen,Hanna Küpper,Birgit Meßmer,Daniela Steuernagel,Sabine Borowski,Christa Bretschneider,Erdmute Roth,Anja Müller,Heike de Vries,Hans Hartmann,Barbara Ramadan,Christoph Kamm,Sophie Fischer,Marieke Wermuth,Ulf Hustedt,Jan Christoph Koch,Mohamad Tareq Muhandes,Tobias Baum,Anna Hotter,Albert Ludolph,Zeljko Uzelac,Simon Witzel,Johannes Dorst,Joachim Schuster,Kurt Wollinsky,Pascal Martin,Alexander Mensch,Steffen Naegel,Ilka Schneider,Thomas Kendzierski,Anna Koelsch,Gerd Meyer zu Hörste,Sarah Wiethoff,Esra Akova-Oztürk,Astrid Blaschek,Iris Hannibal,Birgit Warken-Madelung,Therese Well,Elisabeth Rotenfusser,Maren Nitzsche,Christoph Neuwirth,Nathalie Braun,Zylfie Dibrani,Jasmin Bischofberger,Susanne Petri,Bogdan Bjelica,Camilla Wohnrade,Tilman Riesmeier,Michaela Schwippert,Antonia Leinert,Alma Oscmanovic,Olivia Schreiber-Katz,Astrid Eisenkölbl,Imke Rathmann,Dorothee Schäfer,Adela Della-Marina,Andrea Gangfuß,Britta Holtkamp,Barbara Andres,Isabelle Renger,Daniela Angelova-Toshkina,Lisa Jung,Bertold Schrank,Bernd Wilken,Alma Osmanovic,Barbara Fiedler,Timo Deba,Eva Johann to Settel,Katja Köbbing,Heymut Omran,Hélène Guillemot,Barbara Plecko,Joachim Zobel,Michael Grässl,Sander Claeys,Maja von der Hagen,Jens Schallner,Susan Fiebig,Sandy Foerster,Nicole Claus,Ilka Lehnert,Julie Hammer,Meike Steinbach,Maike Tomforde,Johannes Stoffels,Thomas Voelkl,Christina Kraut,Carmen Hollerauer,Lea Seeber,Mike Grünwedel,Raffi Topakian,Petra Müller,Peter Vollmann,Ina Krahwinkler,Bettina Behring,Stephanie Schüssler,Matthias Türk,Matthias Vorgerd,Anne Güttsches,Melanie Roeder,Irene Lange,Peter Reilich,Miriam Hiebeler,Federica Montagnese,Simone Thiele,Anna Hagenmeyer,Laura Grimm,Corinna Wirner-Piotrowski,Markus Weiler,Wolfgang Wick,Nicole Berberich,Marcel Mann-Richter,Heidi Rochau-Trumpp,Marion Schnurr,Guido Stocker,Corinna Stoltenburg,Joanna Schneider,Alexandra Wagner,Annette George,Vladimir Dukic,Angela M. Kaindl,Lieske van der Stam,Gilbert Wunderlich,Claudia Diana Wurster*,Johannes Dorst*,Joachim Schuster*,Albert Christian Ludolph*,Daniel Zeller,Julia Bellut,Brigitte Brauner,Christine Leypold,Georg Friedrich Hoffmann,Stefan Kölker,Afshin Saffari,Moritz Niesert,Sabine Specht,Annegret Hoevel,Anke Bongartz,Daniela Zöller,Harald Binder,Maren Hackenberg,

DOI: https://doi.org/10.1001/jamapediatrics.2024.0492

2024-04-08

JAMA Pediatrics

Abstract:Importance There is increasing evidence that early diagnosis and treatment are key for outcomes in infants with spinal muscular atrophy (SMA), and newborn screening programs have been implemented to detect the disease before onset of symptoms. However, data from controlled studies that reliably confirm the benefits of newborn screening are lacking. Objective To compare data obtained on patients with SMA diagnosed through newborn screening and those diagnosed after clinical symptom onset. Design, Setting, and Participants This nonrandomized controlled trial used data from the SMARTCARE registry to evaluate all children born between January 2018 and September 2021 with genetically confirmed SMA and up to 3 SMN2 copies. The registry includes data from 70 participating centers in Germany, Austria, and Switzerland. Data analysis was performed in February 2023 so that all patients had a minimal follow-up of 18 months. Exposure Patients born in 2 federal states in Germany underwent screening in a newborn screening pilot project. All other patients were diagnosed after clinical symptom onset. All patients received standard care within the same health care system. Main Outcomes The primary end point was the achievement of motor milestones. Results A total of 234 children (123 [52.6%] female) were identified who met inclusion criteria and were included in the analysis: 44 (18.8%) in the newborn screening cohort and 190 children (81.2%) in the clinical symptom onset cohort. The mean (SD) age at start of treatment with 1 of the approved disease-modifying drugs was 1.3 (2.2) months in the newborn screening cohort and 10.7 (9.1) months in the clinical symptom onset cohort. In the newborn screening cohort, 40 of 44 children (90.9%) gained the ability to sit independently vs 141 of 190 (74.2%) in the clinical symptom onset cohort. For independent ambulation, the ratio was 28 of 40 (63.6%) vs 28 of 190 (14.7%). Conclusions and Relevance This nonrandomized controlled trial demonstrated effectiveness of newborn screening for infants with SMA in the real-world setting. Functional outcomes and thus the response to treatment were significantly better in the newborn screening cohort compared to the unscreened clinical symptom onset group. Trial Registration German Clinical Trials Register: DRKS00012699

pediatrics
Treatment Patterns and Use of Resources in Patients with Tuberous Sclerosis Complex: Insights from the TOSCA Registry

Ruben Marques,Elena Belousoye,Mirjana P. Benedik,Tom Carter,Vincent Cottin,Paolo Curatolo,Maria Dahlin,Lisa D'Amato,Guillaume Beaure d'Augeres,Petrus J. de Vries,Jose C. Ferreira,Martha Feucht,Carla Fladrowski,Christoph Hertzberg,Sergiusz Jozwiak,John A. Lawson,Alfons Macaya,Rima Nabbout,Finbar O'Callaghan,Jiong Qin,Valentin Sander,Matthias Sauter,Seema Shah,Yukitoshi Takahashi,Renaud Touraine,Sotiris Youroukos,Bernard Zonnenberg,John C. Kingswood,Anna C. Jansen,Nobuo Shinohara,Shigeo LIorie,Masaya Kubota,Jun Tohyama,Katsumi Imai,Mari Kaneda,Hideo Kaneko,Yasushi Uchida,Tomoko Kirino,Shoichi Endo,Yoshikazu Inoue,Katsuhisa Uruno,Ayse Serdaroglu,Zuhal Yapici,Banu Anlar,Sakir Altunbasak,Olga Lvova,Oleg Valeryevich Belyaev,Oleg Agranovich,Elena Vladislavovna Levitina,Yulia Vladimirovna Maksimova,Antonina Karas,Yuwu Jiang,Liping Zou,Kaifeng Xu,Yushi Zhang,Guoming Luan,Yuqin Zhang,Yi Wang,Meiling Jin,Dingwei Ye,Weiping Liao,Liemin Zhou,Jie Liu,Jianxiang Liao,Bo Yan,Yanchun Deng,Li Jiang,Zhisheng Liu,Shaoping Huang,Hua Li,Kijoong Kim,Pei-Lung Chen,Hsiu-Fen Lee,Jeng-Dau Tsai,Ching-Shiang Chi,Chao-Ching Huang,Australia Kate Riney,Deborah Yates,Patrick Kwan,Surachai Likasitwattanakul,Charcrin Nabangchang,Lunliya Thampratankul Krisnachai Chomtho,Kamornwan Katanyuwong,Somjit Sriudomkajorn,Jo Wilmshurst,Reeval Segel,Tal Gilboa,Michal Tzadok,Aviva Fattal-Valevski,Panagiotis Papathanasopoulos,Antigone Syrigou Papavasiliou,Stylianos Giannakodimos,Stylianos Gatzonis,Evangelos Pavlou,Meropi Tzoufi,A. M. M. Vergeer,Marc Dhooghe,Helene Verhelst,Filip Roelens,Marie Cecile Nassogne,Pierre Defresne,Liesbeth De Waele,Patricia Leroy,Nathalie Demonceau,Benjamin Legros,Patrick Van Bogaert,Berten Ceulemans,Lina Dom,Pierre Castelnau,Anne De Saint Martin,Audrey Riquet,Mathieu Milh,Claude Cances,Jean-Michel Pedespan,Dorothee Ville,Agathe Roubertie,Stephane Auvin,Patrick Berquin,Christian Richelme,Catherine Allaire,Sophie Gueden,Sylvie Nguyen The Tich,Bertrand Godet,Maria Luz Ruiz Falco Rojas,Jaume Campistol Planas,Antonio Martinez Bermejo,Patricia Smeyers Dura,Susana Roldan Aparicio,Maria Jesus Martinez Gonzalez,Javier Lopez Pison,Manuel Oscar Blanco Barca,Eduardo Lopez Laso,Olga Alonso Luengo,Francisco Javier Aguirre Rodriguez,Ignacio Malaga Dieguez,Ana Camacho Salas,Itxaso Marti Carrera,Eduardo Martinez Salcedo,Maria Eugenia Yoldi Petri,Ramon Cancho Candela,Ines da Conceicao Carrilho,Jose Pedro Vieira,Jose Paulo da Silva Oliveira Monteiro,Miguel Jorge Santos de Oliveira Ferreira Leao,Catarina Sofia Marceano Ribeiro Luis,Carla Pires Mendonca,Milda Endziniene,Jurgis Strautmanis,Inga Talvik,Maria Paola Canevini,Antonio Gambardella,Dario Pruna,Salvatore Buono,Elena Fontana,Bernardo Dalla Bernardina,Carmen Burloiu,Iuliu Stefan Bacos Cosma,Mihaela Adela Vintan,Laura Popescu,Karel Zitterbart,Jaroslava Payerova,Ladislav Bratsky,Zuzana Zilinska,Ursula Gruber-Sedlmayr,Matthias Baumann,Edda Laberlandt,Kevin Rostasy,Ekaterina Pataraia,Frances Elmslie,Clare Ann Johnston,Pamela Crawford,Peter Uldall,Paul Uvebrant,Olof Rask,Marit Bjoernvold,Eylert Brodtkorb,Andreas Sloerdahi,Ragnar Solhoff,Martine Sofie Gilje Jaatun,Marek Mandera,Elzbieta Janina Radzikowska,Mariusz Wysocki,Michael Fischereder,Gerhard Kurlemann,Bernd Wilken,Adelheid Wiemer-Kruel,Klemens Budde,Klaus Marquard,Markus Knuf,Andreas Hahn,Hans Hartmann,Andreas Merkenschlager,Regina Trollmann

DOI: https://doi.org/10.3389/fneur.2019.01144

IF: 3.4

2019-01-01

Frontiers in Neurology

Abstract:Tuberous Sclerosis Complex (TSC) is a rare autosomal-dominant disorder caused by mutations in the TSC1 or TSC2 genes. Patients with TSC may suffer from a wide range of clinical manifestations; however, the burden of TSC and its impact on healthcare resources needed for its management remain unknown. Besides, the use of resources might vary across countries depending on the country-specific clinical practice. The aim of this paper is to describe the use of TSC-related resources and treatment patterns within the TOSCA registry. A total of 2,214 patients with TSC from 31 countries were enrolled and had a follow-up of up to 5 years. A search was conducted to identify the variables containing both medical and non-medical resource use information within TOSCA. This search was performed both at the level of the core project as well as at the level of the research projects on epilepsy, subependymal giant cell astrocytoma (SEGA), lymphangioleiomyomatosis (LAM), and renal angiomyolipoma (rAML) taking into account the timepoints of the study, age groups, and countries. Data from the quality of life (QoL) research project were analyzed by type of visit and age at enrollment. Treatments varied greatly depending on the clinical manifestation, timepoint in the study, and age groups. GAB Aergics were the most prescribed drugs for epilepsy, and mTOR inhibitors are dramatically replacing surgery in patients with SEGA, despite current recommendations proposing both treatment options. mTOR inhibitors are also becoming common treatments in rAML and LAM patients. Forty-two out of the 143 patients (29.4%) who participated in the QoL research project reported inpatient stays over the last year. Data from non-medical resource use showed the critical impact of TSC on job status and capacity. Disability allowances were more common in children than adults (51.1% vs 38.2%). Psychological counseling, social services and social worker services were needed by <15% of the patients, regardless of age. The long-term nature, together with the variability in its clinical manifestations, makes TSC a complex and resource-demanding disease. The present study shows a comprehensive picture of the resource use implications of TSC.
Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism-the Find-AF 2 study-rationale and design

Tobias Uhe,Katrin Wasser,Mark Weber-Krüger,Wolf-Rüdiger Schäbitz,Martin Köhrmann,Johannes Brachmann,Ulrich Laufs,Martin Dichgans,Götz Gelbrich,David Petroff,Christiane Prettin,Dominik Michalski,Andrea Kraft,Thorleif Etgen,Peter D Schellinger,Hassan Soda,Florian Bethke,Michael Ertl,Bernd Kallmünzer,Martin Grond,Katharina Althaus,Gerhard F Hamann,Meinhard Mende,Marcus Wagner,Sonja Gröschel,Timo Uphaus,Klaus Gröschel,Rolf Wachter,Find-AF 2 study group,Marianne Hahn,Frederic Zuhorn,Leonard Wulff,Jorge Plümer,Lena Kok,Marcel Janz,Alkisti Kitsiou,Julian Gehmeyr,Alhuda Dabbagh,Charlotte Huber,Johann Pelz,Katja Wartenberg,Mirko Seidel,Oscar Flissakowski,Anna Goschenhofer,Rabia-Basari Hussain,Ina Kim,Stephan Kinze,Christian Kroneberger,Michale Lingnau,Dennis Lischewski,Florian Muhn,Witold Rogge,Miriam Schieffer,Anuscheh Setayesh-Roonizi,Paul Sparenberg,Jill Marie Schertel,Peter Ringleb,Jan Purrucker,Anne Berberich,Miriam Heyse,Matthias Ungerer,Gregor Bauer,Christine Reichardt,Bernhard Ebel,Dragana Milanković-Eberl,Olav Schwarte,Constanze Höcherl,Eric-Manuel Asch,Luisa Bojtschuk,Maximilian Frey,Tomas Dlouhy,Philipp Patrick Zickler,Barbara Beier,Lino-Dominic Braadt,Inessa Gabrielyan,Pawel Kermer,Matthias Kaste,Ahmed Anter,Corina Stirbulescu,Nataliia Meleshchenco,Friederike Burgholte,Claus Lüers,Thorsten Steiner,Cierpinski,Lichti Mari-Carmen,Lars Bonowski,Hassan Abou Eid,Esteban Vajda-Medina,Mareike Probst,Hisham Essa,Benedikt Frank,Benjamin Stolte,Lennart Milles,Erich Hiermann,Renate Weinhardt Alexandra Rascher,Marius Stan,Stefan Kääb,Lars Kellert,Konstantinos Dimitriadis,Anna Kopczak,Bettina Küster,Moritz Sinner,Ignaz Steiger,Maria Kaffe,Sebastian Clauß,Daniel Janowitz,Raffael Thaler,Peter Schellinger,Jörg Glahn,Jan Schubert,Simone Jenniges,Silke Markmann-Boenke,Anne-Sophie Putzer,Michael Schwarze Vera Straeten,Marcus Wiemer,Kosmas Macha,David Haupenthal,Stefanie Balk,Clara-Sophie Kossel,Georg Häusler,Dominik Lehrieder,Peter Cidlinsky,Christian Hametner,Christine Vogl,Thomas Fischer,Moritz Huttelmaier,Octavian Maniuc Peter Nordbeck,Albrecht von Hardenberg,Martin Jünemann,Tobias Braun,Maxime Viard,Stefan Gerner,AlHaj Omar,Sonja Genau,Linus Olbricht,Matthias Wassenberg,Niklas Langguth,Christian Fräbel,Romy Baumgart,Love-Preet Kalra,Norma Diel,Frank Hoffmann,Bettine Schönmuth,Anja Giebler,Lorenz Weber,Jan Birringer,Sandra Lichte-Schneider,Daniela Hütwohl,Lars Udo Krause,Martina Petersen,Konstantin Kirchmeier,Liubov Novikova,Susanne Müller,Sebastian Schellong,Mirko Brudzinski,Ulrich Gerk,Holger Palisch,Frank R Heinzel,Jana Fett,Avinash Suntha,Katja Burian,Bettina Schmitz,Anna Gutwinski,Veronika Angermüller,Tameem Alhammoud,Hüsniye Cakiroglu,Ullrich Bach,Darius Nabavi,Jens Offermann,Olaf Crome,Boris Dimitrijeski,Carsten Meincke,Gerhard Hamann,Burkhard Alber,Robert Müller,Lars-Peder Pallesen,Volker Pütz,Christian Hartmann,Jörg Berrouschot,Anett Stoll,Janina Keilitz,Dietrich Klunk,Roman Voigt,Andreas Kastrup,Andreas Schröter,Johannes Schmucker,Waltraud Pfeilschifter,Christoffer Krämer,Milena Wiemers,Micha Simon,Alexander Finke,Christian Weiß,Carsten Hobohm,Katrin Naupold,Karen Bley-Renning,Sabrina Winter,Sven Poli,Annerose Mengel,Khouloud Poli,Alexandra Gómez Expósito,Joshua Mbroh,Maria Tieck,Michael Rosenkranz,Stefan Boskamp,Nicolas Ritter,Lena Seibel,Christian Schöps,Rebecca Ketzler,Herbert Nägele,Karsten Sydow,Natalia Kurka,Jan Hendrik Schäfer,Daniel Charisse,Katharina Gruber,Konstantin Kohlhase,Franziska Lieschke,Felix Operhalski,Alexander Seiler,Gabor Petzold,Felix Jürgen Bode,Sebastian Stösser,Julius Meißner,Taraneh Ebrahimi,Julia Nordsiek,Niklas Beckonert,Karin Weissenborn,Gerrit Maximilian Große,Hans Worthmann,Ann-Katrin Hennemann,Svenja Jochmann,Julius Gründahl,Jana Al-Ayoubi,Johanna Ernst,Oliver Bähr,Herbert Gruber,Sonka Benesch,Thomas Pollinger,Nawar Alachkar,Sonia Busch,Steffi Butz,Mathias Forkmann,Christian Mahnkopf,Thomas Mischke,Steffen Schnupp,Götz Thomalla,Milani Deb-Chatterji,Bastian Cheng,Mathias Gelderblom,Julia Hoppe,Märit Jensen,Maximilian Schell,Eckhard Schlemm,Lars Marquardt,Haiko Kazarians,Pia Franziska Rheingans,Kai Hötzer,Dietmar Rose,Tobias Neumann-Haefelin,Jörg Berthel,Lirim Alijaj,Joachim Krug,Margit Niethammer,Géza-Attila Szöllösi,Marc Obermann,Nicoletta Adochitei,Herwig Strik,Arne Lenz,Frank Steigerwald,Jörg Müller,Martin Honermann,Marian Christoph Burgstaller,Rainer Kollmar,Maryam Rashid,Ahmad Ajaz Ganai,Ossendorf,Majda Saric,Karl-Heinz Tischer,Adela Toluli,Frank Arne Wollenweber,Laya Rahban,Thais Portugal Silva,Miri Lee,Matthias Julius Grosch,Jens Minnerup,Jan Liman,Martin Nückel,Magdalena Böhm

DOI: https://doi.org/10.1016/j.ahj.2023.06.016

Abstract:Background: Atrial fibrillation (AF) is one of the most frequent causes of stroke. Several randomized trials have shown that prolonged monitoring increases the detection of AF, but the effect on reducing recurrent cardioembolism, ie, ischemic stroke and systemic embolism, remains unknown. We aim to evaluate whether a risk-adapted, intensified heart rhythm monitoring with consequent guideline conform treatment, which implies initiation of oral anticoagulation (OAC), leads to a reduction of recurrent cardioembolism. Methods: Find-AF 2 is a randomized, controlled, open-label parallel multicenter trial with blinded endpoint assessment. 5,200 patients ≥ 60 years of age with symptomatic ischemic stroke within the last 30 days and without known AF will be included at 52 study centers with a specialized stroke unit in Germany. Patients without AF in an additional 24-hour Holter ECG after the qualifying event will be randomized in a 1:1 fashion to either enhanced, prolonged and intensified ECG-monitoring (intervention arm) or standard of care monitoring (control arm). In the intervention arm, patients with a high risk of underlying AF will receive continuous rhythm monitoring using an implantable cardiac monitor (ICM) whereas those without high risk of underlying AF will receive repeated 7-day Holter ECGs. The duration of rhythm monitoring within the control arm is up to the discretion of the participating centers and is allowed for up to 7 days. Patients will be followed for at least 24 months. The primary efficacy endpoint is the time until recurrent ischemic stroke or systemic embolism occur. Conclusions: The Find-AF 2 trial aims to demonstrate that enhanced, prolonged and intensified rhythm monitoring results in a more effective prevention of recurrent ischemic stroke and systemic embolism compared to usual care.
Epidemiology of 7375 children and adolescents hospitalized with COVID-19 in Germany, reported via a prospective, nationwide surveillance study in 2020–2022

Maren Doenhardt,Markus Hufnagel,Natalie Diffloth,Johannes Hübner,René Mauer,Dominik T. Schneider,Arne Simon,Tobias Tenenbaum,Andreas Trotter,Jakob Armann,Reinhard Berner,Aischa Abuleed,Michal Achenbach,Grazyna Adamiak-Brych,Martina Aderhold,Sandra Akanbi,Madaa Akmeinasi,Norbert Albers,Louisa Ammann-Schnell,Kristin Anders,Theresa Andree,Judith Anhalt,Nils Apel,Stefan Arens,Christoph Aring,Caroline Armbruster,Inken Arnold,Thomas Austgen,Igor Bachmat,Lena Balles,Arne Baltaci,Theresa Baranowski,Sylvia Barth,Stefan Barth,María Paula Bateman Castrillón,Susanne Baumann,Lisa Baumbach,Boris Becker,Angelina Beer,Gerald Beier,Christiane Bell,Antigoni Bellou,Stephanie Bentz,Josephine Berens,Elisabeth Berger,Simon Berzel,Julia Bley,Helga Blumberg,Stefanie Blume,Kai Böckenholt,Andreas Böckmann,Sebastian Bode,Julie Boever,Leonie Böhm,Henning Böhme,Carsten Bölke,Monika-Maria Borchers,Hans Martin Bosse,Michael Böswald,Katharina Botschen,Franka Böttger,Sandra Braun,Britta Brenner,Folke Brinkmann,Beate Bruggmoser,Jürgen Brunner,Florian L. Bucher,Laura Buchtala,Jörg Budde,Reinhard Bullmann,Bernhard Bungert,Dorothea Büsdorf,Lisa Cardellini,Chiara Cattaneo,Cho-Ming Chao,Laura Chaparro,Claus Christians,Kerstin Cremer,Gordana Cvetanovic,Alina Czwienzek,Madura Daluwatta,Gideon de Sousa,Metin Degirmenci,Fenja Dejas,Janne Deutschmann,Ute Deutz,Iryna Dobrianska,Katharina Döhring,Helena Donath,Arne Dresen,Svenja Dreßen,Melissa Drozdek,Jens Dubenhorst,Max Dunker,Heinrich Eberhardt,Franziska Ebert,Hannah Echelmeyer,Kerstin Ehrentraut,Christoph Ehrsam,Thea Angelika Eichelmann,Hanna Ellmann,Matthias Endmann,Stefanie Endres,Elisa Endres,Matthias Engler,Denise Engler,David Eppler,Oxana Erbe,Michael Erdmann,Annika Esser,Stephan Ewest,Philipp Falderbaum,Lena Faßbender,Simone Ferber,Andreas Fiedler,Magdalena Fischer,Doris Fischer,Elisabeth Fischer-Ging,Isabel Fischer-Schmidt,Ann-Sophie Fleischer,Simon Flümann,Denise Focke,Svenja Foth,Réka Fövényesi,Svenja Frank,Christian Fremerey,Holger Frenzke,Peter Freudenberg,Mirjam Freudenhammer,Christina Fritsch,Stefanie Frohn,Sylvia Fuhrmann,Veronika Galajda Pavlíková,Lukas Galow,Monika Gappa,Sabine Gärtner,Hanga Gaspar,Swen Geerken,Julia Gehm,Fabienne Gehrlein,Norbert Geier,Bernd Geißlreiter,Martin Geltinger,Marieke Gerlach,Hubert Gerleve,Carl Germann,Verena Giesen,Anna Girrbach,Katharina Glas,Lena Goetz,Karoline Goj,Christin Goldhardt,Julia Gottschalk,Jan-Felix Gottschlich,Oliver Götz,Katrin Gröger,Sina Gronwald,Anja Große Lordemann,Anneke Grotheer,Kathrin Gruber,Judith Grüner,Mike Grünwedel,Lisa Gu,Joya Gummersbach,Stephan Haag,Silke Haag,Yasmin Hagel,Swantje Hagemann,Ina Hainmann,Nikolaus Halwas,Christof Hanke,Jonas Härtner,Caroline Haselier,Anne Haupt,Marie- Kristin Heffels,Solvej Heidtmann,Anna-Lena Heimer,Christina Heinrich,Annika Heinrich,Lutz Hempel,Christoph Hempel,Silke Hennig,Carolin Herbst,Leonie Herholz,Matthias Hermann,Jan-Simon Hermens,Marc Hertel,Matthias Herzog,Georg Heubner,Julia Hildebrandt,Kai-Alexandra Hilker,Georg Hillebrand,Matthias Himpel,Claudia Hirschhausen,Meike Höfer,Liane Hoffmann,Hans-Georg Hoffmann,Mirjam Höfgen,Nina Hofknecht,Anja Hofmann,Franziska Hofmann,Katharina Holtkamp,Mona Holzinger,Anneke Homburg,Thomas Hoppen,Theresa Horst,Andor Attila Horváth,Markus Hummler,Patrick Hundsdörfer,Dieter Hüseman,Conny Huster,Nora Ido,Phryne Ioannou,Simone Jedwilayties,Nils Jonas,Cornelia Junge,Linda Junghanns,Attila Kádár,Mohammad Kaddour,Lea Kahlenberg,Lukas Kaiser,Petra Kaiser-Labusch,Hermann Kalhoff,Carola Kaltenhauser,Elke Kaluza,Wolfgang Kamin,Cecil Varna Kanann,Marcus Kania,Cecil Varna Kannan,Subha Kanneettukandathil,Hendrik Karpinski,Fabian Kassbeger,Katja Kauertz,Alexandra Kavvalou,Svetlana Kelzon,Immo Kern,Elisabeth Kernen,Mandy Kersten,Marie-Sophie Keßner,Daniel Kever,Carolin Khakzar,Johanna Kim,Linda Kirner,Martin Kirschstein,Natalie Kiss,Richard Kitz,Christine Kleff,Deborah Klein,Leah Bernadette Klingel,Christof Kluthe,Jan Knechtel,Marcel Kneißle,Felix Knirsch,Robin Kobbe,Annemarie Köbsch,Luisa Kohlen,Christina Kohlhauser-Vollmuth,Malte Kohns Vasconcelos,Anne Königs,Florian Konrad,Sabrina Koop,Julia Kopka,Vanessa Kornherr,Anna-Lena Kortenbusch,Robert Kosteczka,Holger Köster,Sascha Kowski,Hanna Kravets,Ewa Krink,Maren Krogh,Rebecca Kuglin,Reinhard Kühl,Alena Kuhlmann,Lea Maria Küpper-Tetzel,Marion Kuska,Sachiko Kwaschnowitz,Martina Lange,Franziska Lankes,Julia Laubenbacher,Gerrit Lautner,Thanh Tung Le,Verena Leykamm,Hanna Libuschewski,Lissy Lichtenstein,Nadine Lienert,Johannes Liese,Ulla Lieser,Ilona Lindl,Torben Lindner,Grischa Lischetzki,Matthias Lohr,Norbert Lorenz,Niko Lorenzen,Meike Löwe,Daniela Lubitz,Maria Lueg,Lisa Luft,Sa Luo,Dominik Lwowsky,Kathrin Machon,Katharina Magin,Thomas Maiberger,Nadine Mand,Andrea Markowsky,Wiebke Maurer,Maximilian Mauritz,Theresa Meinhold,Jochen Meister,Melanie Menden,Veronika Messer,Jochen Meyburg,Ulf Meyer,Meike Meyer,Jens Meyer,Lars Meyer-Dobkowitz,Peter Michel,Marko Mohorovicic,Laura Gabriela Moise,Katharina Mönch,Mathieu Monnheimer,Yvonne Morawski,Anja Morgenbrod,Katrin Moritz,David Muhmann,Barbara Müksch,Stefanie Müller,Celina Müller,Annemarie Müller,Viola Müller,Yvonne Müller,Guido Müller,Kathleen Müller-Franz,Lutz Naehrlich,Katharina Naghed,Nicole Näther,Tereza Nespor,Tatjana Neuhierl,Ann-Cathrine Neukamm,Nam Nguyen,Dirk Nielsen,Klaus Niethammer,Lydia Obernosterer,Bernd Opgen-Rhein,Iris Östreicher,Esra Özdemir,Nadejda Paduraru-Stoian,Monique Palm,Laura Parigger,Nina Pellmann,Theresa Pelster,Ardina Pengu,Falk Pentek,Maurice Petrasch,Antonia Maximina Pfennigs,Aaron Pfisterer,Anne Pfülb,Lisa Piehler,Ursula Pindur,Markus Pingel,Eva Pitsikoulis,Jana Plutowski,Wendy Poot,Silvia Poralla,Johanna Pottiez,Simone Pötzsch,Pablo Pretzel,Clarissa Preuß,Sven Propson,Kateryna Puhachova,Daniela Pütz,Samina Quadri-Niazi,Bernhard Queisser,Jennifer Rambow,Gunnar Rau,Cornelius Rau,Jacqueline Raum,Heike Reck,Victoria Rehmann,Friedrich Reichert,Thomas Reinhardt,Carla Remy,Hanna Renk,Annika Richard,Carolin Richter,Nikolaus Rieber,Sebastian Riedhammer,Hannelore Ringe,Bianca Rippberger,Moritz Rohrbach,Bettina Rokonal,Caroline Rötger,Anne Rothermel,Ricarda Rox,Alexander Rühlmann,Marie-Cecile Ryckmanns,Shahane Safarova,Meila Salem,Demet Sarial,Helena Sartor,Johanna Saxe,Herbert Schade,Miriam Schäfer,Cecilia Scheffler,Lena Brigitte Scheffler,Marija Scheiermann,Sandra Schiele,Katja Schierloh,Markus Schiller,Benjamin Schiller,Ruth Schilling,Christof Schitke,Christian Schlabach,Theresa Schlichting,Christian Schlick,Christina Schlingschröder,Florian Schmid,Bastian Schmidt,Josephine Schneider,Dominik Schneider,Hans-Christoph Schneider,Alexander Schnelke,Axel Schobeß,Lothar Schrod,Arne Schröder,Sophia Schröder,Theresia Schug,Christopher Schulze,Katharina Schuster,Katharina Schütz,Valeria Schwägerl,Christoffer Seidel,Christina Seidel,Sabrina Seidel,Josephin Seidel,Katrin Seringhaus-Förster,Armin Setzer,Ralf Seul,Wael Shabanah,M. Ghiath Shamdeen,Sebastian Sigl,Isabel Simon,Christina Solomou,Ezgi Sönmez,Lisa Spath,Marco Spehl,Thomas Stanjek,Daniel Staude,Janina Steenblock,Sandro Stehle,Michael Steidl,Benedikt Steif,Detlef Stein,Franziska Stein,Mathis Steindor,Frank Stemberg,Susanne Stephan,Astrid Stienen,Antje Stockmann,Ursula Strier,Heidi Ströle,Roman Szudarek,Van Hop Ta,Kader Tan,Rebecca Telaar,Anna Telschow,Lisa Teufel,Stephanie Thein,Lion Gabriel Thiel,Lisa Thiesing,Linda Thomas,Julian Thomas,Christian Timke,Irmgard Toni,Melcan Topuz,Stefanie Trau,Eva Tschiedel,Sinty Tzimou,Felix Uhlemann,Torsten Uhlig,Lieser Ulla,Bartholomäus Urgatz,Nicolaus v. Salis,Sascha v. Soldenhoff,Louisa van Bahlen,Alijda Ingeborg van den Heuvel,Kai Vehse,Rebecca Veit,Joshua Verleysdonk,Andreas Viechtbauer,Simon Vieth,Markus Vogel,Sophia von Blomberg,Kira von der Decken,Christian von Schnakenburg,Julia Wagner,Tatjana Wahjudi,Karin Waldecker,Ulrike Walden,Ulrike Walther,Mona Walther,Christine Wegendt,Götz Wehl,Stefan Weichert,Judith Anne Weiland,Julia Weiß,Laura Wendt,Vera Wentzel,Cornelia Wersal,Ulrike Wetzel,Barbara Wichmann,Katharina Wickert,Sandra Wieland,Christiane Maria Wiethoff,Hanna Wietz,Florian Wild,Rainer Willing,Christian Windischmann,Verena Winkeler,Merle Winkelmann,Sascha Winkler,Laura Wißlicen,Isabel Wormit-Frenzel,Tobias Wowra,Andreas Wroblewski,Dominik Wulf,Donald Wurm,Malin Zaddach,Julia Zahn,Kai Zbieranek,Lara-Sophie Zehnder,Anne Zeller,Martin Zellerhoff,Katharina Zerlik,Johanna Zimmermann,Mária Zimolová,Ulrich Zügge,The DGPI COVID-19 working group

DOI: https://doi.org/10.1038/s41598-023-49210-1

IF: 4.6

2024-01-03

Scientific Reports

Abstract:By means of a nationwide, prospective, multicenter, observational cohort registry collecting data on 7375 patients with laboratory-confirmed SARS-CoV-2 admitted to children's hospitals in Germany, March 2020–November 2022, our study assessed the clinical features of children and adolescents hospitalized due to SARS-CoV-2, evaluated which of these patients might be at highest risk for severe COVID-19, and identified underlying risk factors. Outcomes tracked included: symptomatic infection, case fatality, sequelae at discharge and severe disease. Among reported cases, median age was one year, with 42% being infants. Half were admitted for reasons other than SARS-CoV-2. In 27%, preexisting comorbidities were present, most frequently obesity, neurological/neuromuscular disorders, premature birth, and respiratory, cardiovascular or gastrointestinal diseases. 3.0% of cases were admitted to ICU, but ICU admission rates varied as different SARS-CoV-2 variants gained prevalence. Main risk factors linked to ICU admission due to COVID-19 were: patient age (> 12 and 1–4 years old), obesity, neurological/neuromuscular diseases, Trisomy 21 or other genetic syndromes, and coinfections at time of hospitalization. With Omicron, the group at highest risk shifted to 1–4-year-olds. For both health care providers and the general public, understanding risk factors for severe disease is critical to informing decisions about risk-reduction measures, including vaccination and masking guidelines.

multidisciplinary sciences
5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2

Katharina Vill,Moritz Tacke,Anna König,Matthias Baumann,Manuela Baumgartner,Meike Steinbach,Guenther Bernert,Astrid Blaschek,Marcus Deschauer,Marina Flotats-Bastardas,Johannes Friese,Susanne Goldbach,Martin Gross,René Günther,Andreas Hahn,Tim Hagenacker,Erwin Hauser,Veronka Horber,Sabine Illsinger,Jessika Johannsen,Christoph Kamm,Jan C. Koch,Heike Koelbel,Cornelia Koehler,Kirsten Kolzter,Hanns Lochmüller,Albert Ludolph,Alexander Mensch,Gerd Meyer zu Hoerste,Monika Mueller,Wolfgang Mueller-Felber,Christoph Neuwirth,Susanne Petri,Kristina Probst-Schendzielorz,Manuel Pühringer,Robert Steinbach,Ulrike Schara-Schmidt,Mareike Schimmel,Bertold Schrank,Oliver Schwartz,Kurt Schlachter,Annette Schwerin-Nagel,Gudrun Schreiber,Martin Smitka,Raffi Topakian,Regina Trollmann,Matthias Tuerk,Manuela Theophil,Christian Rauscher,Mathias Vorgerd,Maggie C. Walter,Markus Weiler,Claudia Weiss,Ekkehard Wilichowski,Claudia D. Wurster,Gilbert Wunderlich,Daniel Zeller,Andreas Ziegler,Janbernd Kirschner,Astrid Pechmann,

DOI: https://doi.org/10.1007/s00415-024-12188-5

2024-02-27

Journal of Neurology

Abstract:Abstract Newborn screening for 5qSMA offers the potential for early, ideally pre-symptomatic, therapeutic intervention. However, limited data exist on the outcomes of individuals with 4 copies of SMN2 , and there is no consensus within the SMA treatment community regarding early treatment initiation in this subgroup. To provide evidence-based insights into disease progression, we performed a retrospective analysis of 268 patients with 4 copies of SMN2 from the SMArtCARE registry in Germany, Austria and Switzerland. Inclusion criteria required comprehensive baseline data and diagnosis outside of newborn screening. Only data prior to initiation of disease-modifying treatment were included. The median age at disease onset was 3.0 years, with a mean of 6.4 years. Significantly, 55% of patients experienced symptoms before the age of 36 months. 3% never learned to sit unaided, a further 13% never gained the ability to walk independently and 33% of ambulatory patients lost this ability during the course of the disease. 43% developed scoliosis, 6.3% required non-invasive ventilation and 1.1% required tube feeding. In conclusion, our study, in line with previous observations, highlights the substantial phenotypic heterogeneity in SMA. Importantly, this study provides novel insights: the median age of disease onset in patients with 4 SMN2 copies typically occurs before school age, and in half of the patients even before the age of three years. These findings support a proactive approach, particularly early treatment initiation, in this subset of SMA patients diagnosed pre-symptomatically. However, it is important to recognize that the register will not include asymptomatic individuals.

clinical neurology
[Laryngeal receptors in the expiratory reflex].

J. Widdicombe

Bratislava Medical Journal

Abstract:
Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project)

Roberto Bernabei,Francesco Landi,Riccardo Calvani,Matteo Cesari,Susanna Del Signore,Stefan D Anker,Raphael Bejuit,Philippe Bordes,Antonio Cherubini,Alfonso J Cruz-Jentoft,Mauro Di Bari,Tim Friede,Carmen Gorostiaga Ayestarán,Harmonie Goyeau,Pálmi V Jónsson,Makoto Kashiwa,Fabrizia Lattanzio,Marcello Maggio,Luca Mariotti,Ram R Miller,Leocadio Rodriguez-Mañas,Regina Roller-Wirnsberger,Ingrid Rýznarová,Joachim Scholpp,Annemie M W J Schols,Cornel C Sieber,Alan J Sinclair,Anna Skalska,Timo Strandberg,Achille Tchalla,Eva Topinková,Matteo Tosato,Bruno Vellas,Stephan von Haehling,Marco Pahor,Ronenn Roubenoff,Emanuele Marzetti,SPRINTT consortium,Andeleeb Dahy,Laurent Nicolas,Gianluca Zia,Cinzia Bertuzzi,Sabina De Giorgi,Luca Feletti,Alessandro Loria,Davide Mantovani,Elisa Marchioro,Francesco Mocci,Alberto Sacco,Maria Grazia Varesio,Maxime Billot,Noëlle Cardinaud,Muriel Castelli,Marion Charenton-Blavignac,Cecilia Ciccolari-Micaldi,Thierry Dantoine,Caroline Gayot,Nicolas Giroult,Anael Larreur,Cécilie Laubarie-Mouret,Delphine Marchesseau,Thomas Mergans,Thai Binh Nguyen,Arnaud Papon,Johann Ribet,Isabelle Saulnie,Gabor Abellan Van Kan,Virginie Biville,Lauréane Brigitte,Carole Cervera,Céline Cluzan,Muriel Croizet,Sophie Dardenne,Marie Dorard,Charlotte Dupuy,Emilie Durand,Catherine Faisant,Sophie Guyonnet,Rémi Mauroux,Agathe Milhet,Sylvie Montel,Pierre-Jean Ousset,Cécile Picauron,Gaelle Soriano,Bernard Teysseyre,Sital Harris,Allison Ogborne,Sarah Ritchie,Harriet Sinclair,Lois Tirrell,Caroline Sinclair,Alfredo Cesario,Barbara Cabin,Pim de Boer,Claire Ignaszewski,Ingrid Klingmann,Tina Auerswald,Christof Engel,Anna Franke,Ellen Freiberger,Ulrike Freiheit,Susann Gotthardt,Karin Kampe,Robert Kob,Christine Kokott,Carolin Kraska,Christian Meyer,Veronika Reith,Hanna Rempe,Daniel Schoene,Gabrielle Sieber,Kerstin Zielinski,Nicole Ebner,Michael Benecky,Alejandro Alvarez-Bustos,Cristina Alonso Bouzon,Beatriz Contreras Escamez,Jimmy Gonzales Turin,Olga Laosa Zafra,Myriel Lopez Tatis,Laura Pedraza Sepulveda,Juan Luis Sanchez,Carlos Sanchez Puelles,Juan Álvarez-Santos,Belén Fernández-Jiménez,Jesús Mateos-Del Nozal,Beatriz Montero-Errasquín,Beatriz Ponce-Moreno,Cristina Roldán-Plaza,Alfonso Romera-de Vicente,Vicente Sánchez-Cadenas,Carmen Sánchez-Castellano,Elisabet Sánchez-García,María Nieves Vaquero-Pinto,Sandrine Andrieu,Alessandro Blasimme,Cedric Dray,Emmanuelle Rial-Sebbag,Philippe Valet,Laurence Laigle,Itziar Martinez-Melchor,Belen Surroca,Stefania Ambrosi,Renato Baldoni,Serena Bernabei,Anna Rita Bonfigli,Silvia Bustacchini,Barbara Carrieri,Anna Rita Costantini,Michela Cucchi,Giuseppina Dell'Aquila,Emma Espinosa,Luciano Izzo,Massimiliano Fedecostante,Michela Mannoni,Antonella Mengarelli,Marino Modestino,Emanuele Monterubbianesi,Stefano Piomboni,Antonia Scrimieri,Eddy Severini,Fabiana Mirella Trotta,Lorella Vece,Susanna Venere,Elisa Zengarini,Milan Chang,Hrafnhildur Eymundsdóttir,Ólöf Guðný Geirsdóttir,Steinn Baugur Gunnarsson,Steinunn Guðnadóttir,Alfons Ramel,Konstantín Shcherbak,Gerhard Wirnsberger,Sheena Kao,Romain Barnouin,Lex van Velsenm,Miriam Vollenbroek-Hutten,Christian Asbrand,Sandrine Durand,Florence Joly,Klaus Flechsenhar,Régis Le Lain,Jerome Mshihid,Aurèle Ndja,Ivana Drastichova,Eva Hasaliková,Radim Hucko,Seget Jakub,Monika Janácová,Michaela Kilmková,Martina Parízková,Kristyna Pavelková,Michaela Redrova,Petra Rusková,Michele Basile,Damiano Biscotti,Claudio Boni,Vincenzo Brandi,Marianna Broccatelli,Carilia Celesti,Americo Cicchetti,Hélio Jose Coelho-Junior,Agnese Collamati,Silvia Coretti,Emanuela D'Angelo,Mariaelena D'Elia,Eugenio Di Brino,Giovanni Landi,Anna Maria Martone,Elena Ortolani,Teodosio Pafundi,Cecilia Pantanelli,Anna Picca,Matteo Ruggeri,Filippo Rumi,Sara Salini,Giulia Savera,Elisabetta Serafini,Davide L Vetrano,Fabio Vitale,Elisa Adorni,Fulvio Lauretani,Yari Longobucco,Giovanna Maria Pelà,Sara Tagliaferri,Thomas Rapp,Yves Arrghi,Bastian Ravesteinj,Jérôme Ronchetti,Quittterie Roquebert,Jonathan Sicsic,Nicolas Sirven,Harry Gosker,Jos M G A Schols,Lisanne Schuurman,Nick Smeets,Coby van de Bool,Claire Weling,Katja Hallikas,Marjatta Herranen,Laura Hyvönen,Kirsi Ikonen,Satu Jyväkorpi,Anne Karppi-Sjöblom,Kaisa Karvinen,Tarja Kindstedt,Saana Leirimaa,Hanna Öhman,Kaisu Pitkälä,Anja Punkka,Anna-Maria Saavalainen,Tuulia Salo,Katja Sohlberg,Reijo Tilvis,Annele Urtamo,Hannu Vanhanen,Lucie Bautzká,Tereza Gueye,Ilona Juklíčková,Pavla Mádlová,Helena Mejstříková,Helena Michálková,Eva Klára Novotná,Tereza Vágnerová,Ewa Blaszczyk-Bebenek,Marcin Cwynar,Joanna Czesak,Paulina Fatyga,Malgorzata Fedyk-Lukasik,Tomasz Grodzicki,Paulina Jamrozik,Zbigniew Janusz,Ewa Klimek,Sylwia Komoniewska,Maria Kret,Maciej Ozog,Agnieszka Parnicka,Katarzyna Petitjean,Anna Pietrzyk,Karolina Piotrowicz,Barbara Skalska-Dulinska,Damian Starzyk,Katarzyna Szczerbinska,Borys Witkiewicz,Anna Wlodarczyk,Wieslawa Zgud

DOI: https://doi.org/10.1136/bmj-2021-068788

2022-05-11

BMJ

Abstract:Objective: To determine whether a multicomponent intervention based on physical activity with technological support and nutritional counselling prevents mobility disability in older adults with physical frailty and sarcopenia. Design: Evaluator blinded, randomised controlled trial. Setting: 16 clinical sites across 11 European countries, January 2016 to 31 October 2019. Participants: 1519 community dwelling men and women aged 70 years or older with physical frailty and sarcopenia, operationalised as the co-occurrence of low functional status, defined as a short physical performance battery (SPPB) score of 3 to 9, low appendicular lean mass, and ability to independently walk 400 m. 760 participants were randomised to a multicomponent intervention and 759 received education on healthy ageing (controls). Interventions: The multicomponent intervention comprised moderate intensity physical activity twice weekly at a centre and up to four times weekly at home. Actimetry data were used to tailor the intervention. Participants also received personalised nutritional counselling. Control participants received education on healthy ageing once a month. Interventions and follow-up lasted for up to 36 months. Main outcome measures: The primary outcome was mobility disability (inability to independently walk 400 m in <15 minutes). Persistent mobility disability (inability to walk 400 m on two consecutive occasions) and changes from baseline to 24 and 36 months in physical performance, muscle strength, and appendicular lean mass were analysed as pre-planned secondary outcomes. Primary comparisons were conducted in participants with baseline SPPB scores of 3-7 (n=1205). Those with SPPB scores of 8 or 9 (n=314) were analysed separately for exploratory purposes. Results: Mean age of the 1519 participants (1088 women) was 78.9 (standard deviation 5.8) years. The average follow-up was 26.4 (SD 9.5) months. Among participants with SPPB scores of 3-7, mobility disability occurred in 283/605 (46.8%) assigned to the multicomponent intervention and 316/600 (52.7%) controls (hazard ratio 0.78, 95% confidence interval 0.67 to 0.92; P=0.005). Persistent mobility disability occurred in 127/605 (21.0%) participants assigned to the multicomponent intervention and 150/600 (25.0%) controls (0.79, 0.62 to 1.01; P=0.06). The between group difference in SPPB score was 0.8 points (95% confidence interval 0.5 to 1.1 points; P<0.001) and 1.0 point (95% confidence interval 0.5 to 1.6 points; P<0.001) in favour of the multicomponent intervention at 24 and 36 months, respectively. The decline in handgrip strength at 24 months was smaller in women assigned to the multicomponent intervention than to control (0.9 kg, 95% confidence interval 0.1 to 1.6 kg; P=0.028). Women in the multicomponent intervention arm lost 0.24 kg and 0.49 kg less appendicular lean mass than controls at 24 months (95% confidence interval 0.10 to 0.39 kg; P<0.001) and 36 months (0.26 to 0.73 kg; P<0.001), respectively. Serious adverse events occurred in 237/605 (39.2%) participants assigned to the multicomponent intervention and 216/600 (36.0%) controls (risk ratio 1.09, 95% confidence interval 0.94 to 1.26). In participants with SPPB scores of 8 or 9, mobility disability occurred in 46/155 (29.7%) in the multicomponent intervention and 38/159 (23.9%) controls (hazard ratio 1.25, 95% confidence interval 0.79 to 1.95; P=0.34). Conclusions: A multicomponent intervention was associated with a reduction in the incidence of mobility disability in older adults with physical frailty and sarcopenia and SPPB scores of 3-7. Physical frailty and sarcopenia may be targeted to preserve mobility in vulnerable older people. Trial registration: ClinicalTrials.gov NCT02582138.
The German National Registry of Primary Immunodeficiencies (2012-2017)

Sabine M El-Helou,Anika-Kerstin Biegner,Sebastian Bode,Stephan R Ehl,Maximilian Heeg,Maria E Maccari,Henrike Ritterbusch,Carsten Speckmann,Stephan Rusch,Raphael Scheible,Klaus Warnatz,Faranaz Atschekzei,Renata Beider,Diana Ernst,Stev Gerschmann,Alexandra Jablonka,Gudrun Mielke,Reinhold E Schmidt,Gesine Schürmann,Georgios Sogkas,Ulrich H Baumann,Christian Klemann,Dorothee Viemann,Horst von Bernuth,Renate Krüger,Leif G Hanitsch,Carmen M Scheibenbogen,Kirsten Wittke,Michael H Albert,Anna Eichinger,Fabian Hauck,Christoph Klein,Anita Rack-Hoch,Franz M Sollinger,Anne Avila,Michael Borte,Stephan Borte,Maria Fasshauer,Anja Hauenherm,Nils Kellner,Anna H Müller,Anett Ülzen,Peter Bader,Shahrzad Bakhtiar,Jae-Yun Lee,Ursula Heß,Ralf Schubert,Sandra Wölke,Stefan Zielen,Sujal Ghosh,Hans-Juergen Laws,Jennifer Neubert,Prasad T Oommen,Manfred Hönig,Ansgar Schulz,Sandra Steinmann,Klaus Schwarz,Gregor Dückers,Beate Lamers,Vanessa Langemeyer,Tim Niehues,Sonu Shai,Dagmar Graf,Carmen Müglich,Marc T Schmalzing,Eva C Schwaneck,Hans-Peter Tony,Johannes Dirks,Gabriele Haase,Johannes G Liese,Henner Morbach,Dirk Foell,Antje Hellige,Helmut Wittkowski,Katja Masjosthusmann,Michael Mohr,Linda Geberzahn,Christian M Hedrich,Christiane Müller,Angela Rösen-Wolff,Joachim Roesler,Antje Zimmermann,Uta Behrends,Nikolaus Rieber,Uwe Schauer,Rupert Handgretinger,Ursula Holzer,Jörg Henes,Lothar Kanz,Christoph Boesecke,Jürgen K Rockstroh,Carolynne Schwarze-Zander,Jan-Christian Wasmuth,Dagmar Dilloo,Brigitte Hülsmann,Stefan Schönberger,Stefan Schreiber,Rainald Zeuner,Tobias Ankermann,Philipp von Bismarck,Hans-Iko Huppertz,Petra Kaiser-Labusch,Johann Greil,Donate Jakoby,Andreas E Kulozik,Markus Metzler,Nora Naumann-Bartsch,Bettina Sobik,Norbert Graf,Sabine Heine,Robin Kobbe,Kai Lehmberg,Ingo Müller,Friedrich Herrmann,Gerd Horneff,Ariane Klein,Joachim Peitz,Nadine Schmidt,Stefan Bielack,Ute Groß-Wieltsch,Carl F Classen,Jessica Klasen,Peter Deutz,Dirk Kamitz,Lisa Lassay,Klaus Tenbrock,Norbert Wagner,Benedikt Bernbeck,Bastian Brummel,Eusebia Lara-Villacanas,Esther Münstermann,Dominik T Schneider,Nadine Tietsch,Marco Westkemper,Michael Weiß,Christof Kramm,Ingrid Kühnle,Silke Kullmann,Hermann Girschick,Christof Specker,Elisabeth Vinnemeier-Laubenthal,Henriette Haenicke,Claudia Schulz,Lothar Schweigerer,Thomas G Müller,Martina Stiefel,Bernd H Belohradsky,Veronika Soetedjo,Gerhard Kindle,Bodo Grimbacher

DOI: https://doi.org/10.3389/fimmu.2019.01272

2019-07-19

Abstract:Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs. Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel. Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1-25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0-88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%-subcutaneous; 29%-intravenous; 1%-unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy. Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex.

Anna C. Jansen,Elena Belousova,Mirjana P. Benedik,Tom Carter,Vincent Cottin,Paolo Curatolo,Maria Dahlin,Lisa D'Amato,Guillaume Beaure d'Augeres,Petrus J. de Vries,Jose C. Ferreira,Martha Feucht,Carla Fladrowski,Christoph Hertzberg,Sergiusz Jozwiak,John A. Lawson,Alfons Macaya,Ruben Marques,Rima Nabbout,Finbar O'Callaghan,Jiong Qin,Valentin Sander,Matthias Sauter,Seema Shah,Yukitoshi Takahashi,Renaud Touraine,Sotiris Youroukos,Bernard Zonnenberg,John C. Kingswood,Nobuo Shinohara,Shigeo Horie,Masaya Kubota,Jun Tohyama,Katsumi Imai,Mari Kaneda,Hideo Kaneko,Yasushi Uchida,Tomoko Kirino,Shoichi Endo,Yoshikazu Inoue,Katsuhisa Uruno,Ayse Serdaroglu,Zuhal Yapici,Banu Anlar,Sakir Altunbasak,Olga Lvova,Oleg Valeryevich Belyaev,Oleg Agranovich,Elena Vladislavovna Levitina,Yulia Vladimirovna Maksimova,Antonina Karas,Yuwu Jiang,Liping Zou,Kaifeng Xu,Yushi Zhang,Guoming Luan,Yuqin Zhang,Yi Wang,Meiling Jin,Dingwei Ye,Weiping Liao,Liemin Zhou,Jie Liu,Jianxiang Liao,Bo Yan,Yanchun Deng,Li Jiang,Zhisheng Liu,Shaoping Huang,Hua Li,Kijoong Kim,Pei-Lung Chen,Hsiu-Fen Lee,Jeng-Dau Tsai,Ching-Shiang Chi,Chao-Ching Huang,Kate Riney,Deborah Yates,Patrick Kwan,Surachai Likasitwattanakul,Charcrin Nabangchang,Lunliya Thampratankul Krisnachai Chomtho,Kamornwan Katanyuwong,Somjit Sriudomkajorn,Jo Wilmshurst,Reeval Segel,Tal Gilboa,Michal Tzadok,Aviva Fattal-Valevski,Panagiotis Papathanasopoulos,Antigone Syrigou Papavasiliou,Stylianos Giannakodimos,Stylianos Gatz,Evangelos Pavlou,Meropi Tzoufi,A. M. H. Vergeer,Marc Dhooghe,Helene Verhelst,Filip Roelens,Marie Cecile Nassogne,Pierre Defresne,Liesbeth De Waele,Patricia Leroy,Nathalie Demonceau,Benjamin Legros,Patrick Van Bogaert,Berten Ceulemans,Lina Dom,Pierre Castelnau,Anne De St Martin,Audrey Riquet,Mathieu Milh,Claude Cances,Jean-Michel Pedespan,Dorothee Ville,Agathe Roubertie,Stephane Auvin,Patrick Berquin,Christian Richelme,Catherine Allaire,Sophie Gueden,Sylvie Nguyen The Tich,Bertrand Godet,Maria Luz Ruiz Falco Rojas,Jaume Campistol Planas,Antonio Martinez Bermejo,Patricia Smeyers Dura,Susana Roldan Aparicio,Maria Jesus Martinez Gonzalez,Javier Lopez Pison,Manuel Oscar Blanco Barca,Eduardo Lopez Laso,Olga Alonso Luengo,Francisco Javier Aguirre Rodriguez,Ignacio Malaga Dieguez,Ana Camacho Salas,Itxaso Marti Carrera,Eduardo Martinez Salcedo,Maria Eugenia Yoldi Petri,Ramon Cancho Candela,Ines da Conceicao Carrilho,Jose Pedro Vieira,Jose Paulo da Silva Oliveira Monteiro,Miguel Jorge Santos de Oliveira Ferreira Leao,Catarina Sofia Marceano Ribeiro Luis,Carla Pires Mendonca,Milda Endziniene,Jurgis Strautmanis,Inga Talvik,Maria Paola Canevini,Antonio Gambardella,Dario Pruna,Salvatore Buono,Elena Fontana,Bernardo Dalla Bernardina,Carmen Burloiu,Iuliu Stefan Bacos Cosma,Mihaela Adela Vintan,Laura Popescu,Karel Zitterbart,Jaroslava Payerova,Ladislav Bratsky,Zuzana Zilinska,Ursula Gruber-Sedlmayr,Matthias Baumann,Edda Haberland,Kevin Rostasy,Ekaterina Pataraia,Frances Elmslie,Clare Ann Johnston,Pamela Crawford,Peter Uldall,Paul Uvebrant,Olof Rask,Marit Bjoernvold,Eylert Brodtkorb,Andreas Sloerdahl,Ragnar Solhoff,Martine Sofie Gilje Jaatun,Marek Mandera,Elzbieta Janina Radzikowska,Mariusz Wysocki,Michael Fischereder,Gerhard Kurlemann,Bernd Wilken,Adelheid Wiemer-Kruel,Klemens Budde,Klaus Marquard,Markus Knuf,Andreas Hahn,Hans Hartmann,Andreas Merkenschlager,Regina Trollmann

DOI: https://doi.org/10.3389/fneur.2019.00705

IF: 3.4

2019-01-01

Frontiers in Neurology

Abstract:Background: This study evaluated the characteristics of subependymal giant cell astrocytoma (SEGA) in patients with tuberous sclerosis complex (TSC) entered into the TuberOus SClerosis registry to increase disease Awareness (TOSCA).Methods: The study was conducted at 170 sites across 31 countries. Data from patients of any age with a documented clinical visit for TSC in the 12 months preceding enrollment or those newly diagnosed with TSC were entered.Results: SEGA were reported in 554 of 2,216 patients (25%). Median age at diagnosis of SEGA was 8 years (range, <1–51), with 18.1% diagnosed after age 18 years. SEGA growth occurred in 22.7% of patients aged ≤ 18 years and in 11.6% of patients aged > 18 years. SEGA were symptomatic in 42.1% of patients. Symptoms included increased seizure frequency (15.8%), behavioural disturbance (11.9%), and regression/loss of cognitive skills (9.9%), in addition to those typically associated with increased intracranial pressure. SEGA were significantly more frequent in patients with TSC2 compared to TSC1 variants (33.7 vs. 13.2 %, p < 0.0001). Main treatment modalities included surgery (59.6%) and mammalian target of rapamycin (mTOR) inhibitors (49%).Conclusions: Although SEGA diagnosis and growth typically occurs during childhood, SEGA can occur and grow in both infants and adults.
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT

Anthony A Amato,Michael G Hanna,Pedro M Machado,Umesh A Badrising,Hector Chinoy,Olivier Benveniste,Ananda Krishna Karanam,Min Wu,László B Tankó,Agnes Annette Schubert-Tennigkeit,Dimitris A Papanicolaou,Thomas E Lloyd,Merrilee Needham,Christina Liang,Katrina A Reardon,Marianne de Visser,Dana P Ascherman,Richard J Barohn,Mazen M Dimachkie,James A L Miller,John T Kissel,Björn Oskarsson,Nanette C Joyce,Peter Van den Bergh,Jonathan Baets,Jan L De Bleecker,Chafic Karam,William S David,Massimiliano Mirabella,Sharon P Nations,Hans H Jung,Elena Pegoraro,Lorenzo Maggi,Carmelo Rodolico,Massimiliano Filosto,Aziz I Shaibani,Kumaraswamy Sivakumar,Namita A Goyal,Madoka Mori-Yoshimura,Satoshi Yamashita,Naoki Suzuki,Masashi Aoki,Masahisa Katsuno,Hirokazu Morihata,Kenya Murata,Hiroyuki Nodera,Ichizo Nishino,Carla D Romano,Valerie S L Williams,John Vissing,Lixin Zhang Auberson,RESILIENT Study Extension Group,Susan Walters,Dave Hathorn,Sam Salman,Melanie Burk,Ruby Chen,Mary Jenkins,Carolyn Sue,Susan Mathers,Ruth Krasniqi,Lisa Mottram,Katie Fitzgerald,James Howe,Hanne Files,Linda Wagemaekers,Peter De Jonghe,Delphine Mahieu,Tom Heremans,Kathy de Koning,Katrien De Mey,Stefanie Cardoen,Chantal Miclotte,Marie-Odile Bioul,Anne Mette Autzen,Julia Rebecka Dahlqvist,Martin Jorsal,Nanna Witting,Jane Pedersen,Kirsten Knak,Linda Andersen,Maj-Brit Tanderup Joergensen,Jean Yves Hogrel,Laurent Gilardin,Gwenn Ollivier,Nicolas Champtiaux,Valérie Decostre,Aude Rigolet,Charlotte Lilien,Yves Allenbach,Anne Simon,Damien Bachasson,Chiara De Fino,Matteo Lucchini,Assunta Bianco,Francesco Losavio,Luca Bello,Ilaria Martinelli,Claudio Semplicini,Alessandra Gaiani,Marta Ballabio,Chiara Bussolino,Angela Campanella,Maria Pasanisi,Simona Portaro,Filippo Cavallaro,Fiammetta Biasini,Daniela Parisi,Alice Todeschini,Irene Volonghi,Silvia Rota,Simona Damioli,Hiroya Ono,Tomomi Shijo,Rumiko Izumi,Tetsuya Akiyama,Kensuke Ikeda,Noritaka Wakasugi,Tomoya Kawazoe,Asami Tasaki,Miho Murata,Takako Saotome,Yuki Aihara,Yosuke Ariake,Mai Fujiwara,Mizuki Takeuchi,Takayuki Tateishi,Koyo Tsujikawa,Kuniyuki Endo,Aya Ogura,Seiya Noda,Hirotaka Nakanishi,Kazuhiro Ikumi,Daisuke Ito,Makoto Hattori,Kiyoaki Takeda,Kenji Yoshimura,Rie Kanki,Michiyo Taniguchi,Satoshi Nakano,Maiko Hayashi,Minako Wada,Ayumi Murakami,Masaya Hironishi,Yasuhiro Hiwatani,Masaaki Yasui,Masae Izawa,Jinsoo Koh,Maki Hosokawa,Megumi Mori,Yoshiaki Nakayama,Shoko Yorozu,Junko Taruya,Chigusa Ohno,Shinji Kawasaki,Yukihide Nishimura,Yoshimichi Miyazaki,Naoko Matsui,Hiroki Yamazaki,Taiki Furumoto,Teruaki Masuda,Yasuhiro Yonemochi,Nozomu Tawara,Koutarou Takamatsu,Marjolein van Heur-Neuman,Zaida Koeks,Chiara Straathof,Martha Mosselman,Yvonne Krom,Alexander Lipka,E Strijbos,E Niks,J Verschuuren,Filip Eftimov,Guido Clerx,Tamar Gibson,Anneke van der Kooi,Barbara Christen,Jens Petersen,Evelyne Cataldo,Dan Nguyen-Kim,Gustav Andreisek,Sebastian Frese,Violeta Mihaylova,Kallies Diana,Sandro Mueller,Andrea Boehler,Laura Hennelly,Natalia Budnik,Liying Xing,Kerry Guile,Cathleen Chabo,Heather Hunter,Dorothy Carman,Helen Pilkington,Maria Price,Philip Brown,Ann McNichol,Rory Durcan,Angela Green,Fairbarin Smith,Kathryn Walker,Sean O'Dowd,Louise Wibin,Ann Mcnichol,Claire McDonald,Julie Chadwick,S M Ammar Raza,Mahrajan Raman,Catherine Lambe,Hilary Prais,Nikki Harwood,Ammar Rita,Maharajan Raman,Diane Vassallo,James Lilleker,Shirley Caldwell,Armgan Khan,Andres Keichian,Mohanad Alzubaidi,Yeni Villegas,Allen Tupue,Ali Habeeb,Gaurika Bhagi,Kristen Beck,Tatiana Burbar,Leigh Mauldin,Zina Rasheed,Nancy Cline,Piper Harris,Kristy Osgood,Preethi Nimalka Sivakumar,Kulette Bootka,Vinodh Narayanan,Sidney Spector,Christine Kline,Mark Gonzalez,Mamatha Pasnoor,Jeffrey Statland,Maureen Walsh,Melenie Glen,Melissa Currence,Laura Herbelin,Mazen Dimachkie,Gabrielle Rico,Ayla McCalley,Katie Amato,Nikita Shah,Kevin Zinchuk,Kristen Roe,Jessica Rydingsward,Mohammed Salajegheh,Samantha Chused,Katherine Mirch,Thomas Cochrane,Patricia Flynn,Amanda Guidon,Sarah Cornacchio,Fernando Gonterman,Amy Ellrodt,Magen Bissell,Tyler Watkins,Ashley Robichaud,Grace Bwala,Katharine Nicholson,Patricia Andres,Melissa Arnold,Jaya Trivedi,Lauren Phillips,Sharon Chelnick,Adam Quick,Julie Agriesti,Filiz Muharrem,Miriam Freimer,Stanley Iyadurai,Wendy King,Amro Stino,Louise Mezache,Veena Matthew,Veronica Martin,Tahseen Mozaffar,Tiyonnoh Cash,Trisha Hufnagel,Caroline Peyronnard,Sonia Nayyar,Bethly Aubourg,Judith Pignac-Kobinger,Alexandra Almahuer,Alexyz Milian,Chelsea Miller,Eric Greidinger,Lisa Harlow,Kristen Riley,Lora Clawson,Alpa Uchil,Lisa Christopher-Stine,Rachel Slusher,Sowmya Kumble,Julie Khoury,Harpreet Kaur,Diana Dimitrova,Brooke Bernard,Colleen Anthonisen,Natasha Sundby,Erica Goude,Candace Aguilar,Carly Davis,Jaijeet Toor,Randev Sandhu,Linda Johnson,Michelle Cregan,Sasa Yang,Sarah Macabales,Corey Owens,Criag Mcdonald,James Ha,Lisa Williams,Alina Nicorici,Eric Henricson

DOI: https://doi.org/10.1212/WNL.0000000000011626

IF: 9.9

2021-03-23

Neurology

Abstract:Objective: To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). Methods: Participants (aged 36-85 years) who completed the core study (RESILIENT [Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients]) were invited to join an extension study. Individuals continued on the same treatment as in the core study (10 mg/kg, 3 mg/kg, 1 mg/kg bimagrumab or matching placebo administered as IV infusions every 4 weeks). The co-primary outcome measures were 6-minute walk distance (6MWD) and safety. Results: Between November 2015 and February 2017, 211 participants entered double-blind placebo-controlled period of the extension study. Mean change in 6MWD from baseline was highly variable across treatment groups, but indicated progressive deterioration from weeks 24-104 in all treatment groups. Overall, 91.0% (n = 142) of participants in the pooled bimagrumab group and 89.1% (n = 49) in the placebo group had ≥1 treatment-emergent adverse event (AE). Falls were slightly higher in the bimagrumab 3 mg/kg group vs 10 mg/kg, 1 mg/kg, and placebo groups (69.2% [n = 36 of 52] vs 56.6% [n = 30 of 53], 58.8% [n = 30 of 51], and 61.8% [n = 34 of 55], respectively). The most frequently reported AEs in the pooled bimagrumab group were diarrhea 14.7% (n = 23), involuntary muscle contractions 9.6% (n = 15), and rash 5.1% (n = 8). Incidence of serious AEs was comparable between the pooled bimagrumab and the placebo group (18.6% [n = 29] vs 14.5% [n = 8], respectively). Conclusion: Extended treatment with bimagrumab up to 2 years produced a good safety profile and was well-tolerated, but did not provide clinical benefits in terms of improvement in mobility. The extension study was terminated early due to core study not meeting its primary endpoint. Clinical trial registration: Clinicaltrials.gov identifier NCT02573467. Classification of evidence: This study provides Class IV evidence that for patients with sIBM, long-term treatment with bimagrumab was safe, well-tolerated, and did not provide meaningful functional benefit. The study is rated Class IV because of the open-label design of extension treatment period 2.
Postoperative Complications and Mobilization Following Major Abdominal Surgery With Versus Without Fitness Tracker-based Feedback (EXPELLIARMUS): A Student-led Multicenter Randomized Controlled Clinical Trial of the CHIR-Net SIGMA Study Group

Andre L Mihaljevic,CHIR-Net SIGMA Study Group,Mihaljevic André,Brindl Niall,Frey Pia-Elena,Friedrich Mirco,Gläser Nico,Gsenger Julia,Joos Maximilian,Kuner Charlotte,Leichtle Franziska,Pilgrim Max,Rösch Thomas,Schwab Marius,Studier-Fischer Alexander,Tu Thomas,Doerr-Harim Colette,Tenckhoff Solveig,Feißt Manuel,Klose Christina,Vey Johannes,Beck Lydia,Dimitrova Radina-Ivaylova,Jerger Pia,Kirschall Johanna,Kosmidou Anastasia,Röder Sonja,Schuhmacher Julia-Franziska,Seiboldt Till,Steidle Christoph,Wiesenberger Rico,Axt Steffen,Höver Celine,Riecke Jana,Von Wedel Dario,Wolff Constantin,Zollfrank Julia,Babigian Julia,Bernhardt Robert,De Albuquerque Leinenbach Anne Marie Desiree,Freimark Gerlinde,Hambitzer Felix,Katsara-Antonakea Niki,Kloepfel Hanna,Kraume Johannes,Krug Niklas,Lewin Daniel,Schefold Marc,Schenkenberger Philip,Schmargon Rachel,Speckmann Clara Friederike,Weber Lisa-Marie,Woamey Jonas,Von Lipinski Vincent-Noah,Neudecker Jens,Nguyen Viet Hoang,Al-Wassiti Mariam,Kunik Patrick,Mertig Leon Niklas,Faqar-Uz-Zaman Sara Fatima,Berkarda Zeynep,Rocher Liesa Margarete,Diener Markus,Gerdes Christoph,Heisler Sophie,Aicher Marie Louise,Aperdannier Lena,Dölker Tammy,George Elisabeth,Möbus Christa,Plöger Hannah,Pilz Elisa,Plöger Ruben,Sassenrath Katharina,Scheele Dominik,Spinn Anna,Zech Christoph,Von Heesen Maximilian,Emons Georg,Kosch Ricardo,Gedeon Naomi,Linden Gideon,Kühn Kjell,Tachezy Michael,Psathakis Nikolas,Schroeter Andreas,Berndt Patrick,Gries Sarah,Gruber Lisa,Kleinert Julia,Messerer Jil,Preiser Claudia,Reimelt Alex Michael,Schneider Hannah,Thavarasa Ajith,Werthschulte Moritz Daniel,Vondran Florian,Braun Melissa,Kunder Charlotte,Baumgärtner Kilian,Belosevic Amelie Sophie,Betge Fynn,Blobner Sven,Böhnlein Jonas,Dunkel Yannick,Forster Sebastian,Funk Cornelius,Guo Huilin,Biyan Nathanael Harapan,Henneken Sophie,Hubert Max,Iser Florian,Josten Julia,Kaduk Carolin,Kapell Hannah,Kim Ji,Young,Klein Lukas,Köhler Clara,Köpfer Felix,Lantwin Philippa,Liszowski Julia,Merz Daniela,Nguyen Linh-Cathrin,Parsons Zoe,Pfeiffer Vanessa,Prechal Daniela,Rothenberger Rebecca,Rümmele-Vogt Anna,Schmalzridt Jonathan,Schuhmacher Corinna,Sonntag Nikolai,Stille Malko,Töllner Maximilian,Van Eickels Deborah,Waizy Omrahn,Wen Virginia,Klotz Rosa,Gundlach Jan-Paul,Wehking Felix,Becker Thomas,Voigt Jonas,Schütze Leon,Fröhlich Melissa Kathrin,Zehetmeier Fiona,Stelzner Emma Sophia,Skaberna Lisa,Steffen Patrizia,Zähring Lukas,Riedel Anna,Herrle Florian,Meyer-Gehlen Corinna,Obereisenbuchner Florian,Wehn Antonia,Fichaux Quentin,Michalski Morgana,Schönberger Max,Kappenberger Alina,Schirren Malte,Zimmermann Petra,Erichsen Meret,Behr Jonathan,Gerich Samira,Hägele Janina,Hüsken Dominik,Ismail Majd,Karras Luise,Kastratovic Natalija,Lessing Pascal,Zaimi Marin,Zhang Linyun,Denzinger Maximilian,Graf Sandra,Heger Patrick,Nasir Nadir,Radmann Dan

DOI: https://doi.org/10.1097/SLA.0000000000006232

2024-08-01

Abstract:Objective: To determine whether daily postoperative step goals and feedback through a fitness tracker (FT) reduce the rate of postoperative complications after surgery. Background: Early and enhanced postoperative mobilization has been advocated to reduce postoperative complications, but it is unknown whether FT alone can reduce morbidity. Methods: EXPELLIARMUS was performed at 11 University Hospitals across Germany by the student-led clinical trial network SIGMA. Patients undergoing major abdominal surgery were enrolled, equipped with an FT, and randomly assigned to the experimental (visible screen) or control intervention (blackened screen). The experimental group received daily step goals and feedback through the FT. The primary end point was postoperative morbidity within 30 days using the Comprehensive Complication Index (CCI). All trial visits were performed by medical students in the hospital with the opportunity to consult a surgeon-facilitator who also obtained informed consent. After discharge, medical students performed the 30-day postoperative visit through telephone and electronic questionnaires. Results: A total of 347 patients were enrolled. Baseline characteristics were comparable between the 2 groups. The mean age of patients was 58 years, and 71% underwent surgery for malignant disease, with the most frequent indications being pancreatic, colorectal, and hepatobiliary malignancies. Roughly one-third of patients underwent laparoscopic surgery. No imputation for the primary end point was necessary as data completeness was 100%. There was no significant difference in the CCI between the 2 groups in the intention-to-treat analysis (mean±SD CCI experimental group: 23±24 vs. control: 22±22; 95% CI: -6.1, 3.7; P=0.628). All secondary outcomes, including quality of recovery, 6-minute walking test, length of hospital stay, and step count until postoperative day 7 were comparable between the 2 groups. Conclusions: Daily step goals combined with FT-based feedback had no effect on postoperative morbidity. The EXPELLIARMUS shows that medical students can successfully conduct randomized controlled trials in surgery.
TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study

Petrus J de Vries,Elena Belousova,Mirjana P Benedik,Tom Carter,Vincent Cottin,Paolo Curatolo,Maria Dahlin,Lisa D'Amato,Guillaume B d'Augères,José C Ferreira,Martha Feucht,Carla Fladrowski,Christoph Hertzberg,Sergiusz Jozwiak,J Chris Kingswood,John A Lawson,Alfons Macaya,Ruben Marques,Rima Nabbout,Finbar O'Callaghan,Jiong Qin,Valentin Sander,Matthias Sauter,Seema Shah,Yukitoshi Takahashi,Renaud Touraine,Sotiris Youroukos,Bernard Zonnenberg,Anna C Jansen,TOSCA Consortium and TOSCA Investigators,Nobuo Shinohara,Shigeo Horie,Masaya Kubota,Jun Tohyama,Katsumi Imai,Mari Kaneda,Hideo Kaneko,Yasushi Uchida,Tomoko Kirino,Shoichi Endo,Yoshikazu Inoue,Katsuhisa Uruno,Ayse Serdaroglu,Zuhal Yapici,Banu Anlar,Sakir Altunbasak,Olga Lvova,Oleg Valeryevich Belyaev,Oleg Agranovich,Elena Vladislavovna Levitina,Yulia Vladimirovna Maksimova,Antonina Karas,Yuwu Jiang,Liping Zou,Kaifeng Xu,Yushi Zhang,Guoming Luan,Yuqin Zhang,Yi Wang,Meiling Jin,Dingwei Ye,Weiping Liao,Liemin Zhou,Jie Liu,Jianxiang Liao,Bo Yan,Yanchun Deng,Li Jiang,Zhisheng Liu,Shaoping Huang,Hua Li,Kijoong Kim,Pei-Lung Chen,Hsiu-Fen Lee,Jeng-Dau Tsai,Ching-Shiang Chi,Chao-Ching Huang,Kate Riney,Deborah Yates,Patrick Kwan,Surachai Likasitwattanakul,Charcrin Nabangchang,Lunliya Thampratankul Krisnachai Chomtho,Kamornwan Katanyuwong,Somjit Sriudomkajorn,Jo Wilmshurst,Reeval Segel,Tal Gilboa,Michal Tzadok,Aviva Fattal-Valevski,Panagiotis Papathanasopoulos,Antigone Syrigou Papavasiliou,Stylianos Giannakodimos,Stylianos Gatzonis,Evangelos Pavlou,Meropi Tzoufi,A M H Vergeer,Marc Dhooghe,Hélène Verhelst,Filip Roelens,Marie Cecile Nassogne,Pierre Defresne,Liesbeth De Waele,Patricia Leroy,Nathalie Demonceau,Benjamin Legros,Patrick Van Bogaert,Berten Ceulemans,Lina Dom,Pierre Castelnau,Anne De Saint Martin,Audrey Riquet,Mathieu Milh,Claude Cances,Jean-Michel Pedespan,Dorothee Ville,Agathe Roubertie,Stéphane Auvin,Patrick Berquin,Christian Richelme,Catherine Allaire,Sophie Gueden,Sylvie Nguyen The Tich,Bertrand Godet,Maria Luz Ruiz Falco Rojas,Jaume Campistol Planas,Antonio Martinez Bermejo,Patricia Smeyers Dura,Susana Roldan Aparicio,Maria Jesus Martinez Gonzalez,Javier Lopez Pison,Manuel Oscar Blanco Barca,Eduardo Lopez Laso,Olga Alonso Luengo,Francisco Javier Aguirre Rodriguez,Ignacio Malaga Dieguez,Ana Camacho Salas,Itxaso Marti Carrera,Eduardo Martinez Salcedo,Maria Eugenia Yoldi Petri,Ramon Cancho Candela,Ines da Conceicao Carrilho,Jose Pedro Vieira,José Paulo da Silva Oliveira Monteiro,Miguel Jorge Santos de Oliveira Ferreira Leao,Catarina Sofia Marceano Ribeiro Luis,Carla Pires Mendonca,Milda Endziniene,Jurgis Strautmanis,Inga Talvik,Maria Paola Canevini,Antonio Gambardella,Dario Pruna,Salvatore Buono,Elena Fontana,Bernardo Dalla Bernardina,Carmen Burloiu,Iuliu Stefan Bacos Cosma,Mihaela Adela Vintan,Laura Popescu,Karel Zitterbart,Jaroslava Payerova,Ladislav Bratsky,Zuzana Zilinska,Ursula Gruber-Sedlmayr,Matthias Baumann,Edda Haberlandt,Kevin Rostasy,Ekaterina Pataraia,Frances Elmslie,Clare Ann Johnston,Pamela Crawford,Peter Uldall,Paul Uvebrant,Olof Rask,Marit Bjoernvold,Eylert Brodtkorb,Andreas Sloerdahl,Ragnar Solhoff,Martine Sofie Gilje Jaatun,Marek Mandera,Elzbieta Janina Radzikowska,Mariusz Wysocki,Michael Fischereder,Gerhard Kurlemann,Bernd Wilken,Adelheid Wiemer-Kruel,Klemens Budde,Klaus Marquard,Markus Knuf,Andreas Hahn,Hans Hartmann,Andreas Merkenschlager,Regina Trollmann

DOI: https://doi.org/10.1186/s13023-018-0901-8

2018-09-10

Abstract:Background: Most evidence for TSC-associated neuropsychiatric disorders (TAND) to date have come from small studies and case reports, and very little is known about TAND in adults. We explored baseline TAND data from the large-scale international TOSCA natural history study to compare childhood and adult patterns, describe age-based patterns, and explore genotype-TAND correlations. Results: The study enrolled 2216 eligible participants with TSC from 170 sites across 31 countries at the data cut-off for the third interim analysis (data cut-off date: September 30, 2015). The most common behavioural problems (reported in > 10% of participants) were overactivity, sleep difficulties, impulsivity, anxiety, mood swings, severe aggression, depressed mood, self-injury, and obsessions. Psychiatric disorders included autism spectrum disorder (ASD, 21.1%), attention deficit hyperactivity disorder (ADHD, 19.1%), anxiety disorder (9.7%), and depressive disorder (6.1%). Intelligence quotient (IQ) scores were available for 885 participants. Of these, 44.4% had normal IQ, while mild, moderate, severe, and profound degrees of intellectual disability (ID) were observed in 28.1, 15.1, 9.3, and 3.1%, respectively. Academic difficulties were identified in 58.6% of participants, and neuropsychological deficits (performance <5th percentile) in 55.7%. Significantly higher rates of overactivity and impulsivity were observed in children and higher rates of anxiety, depressed mood, mood swings, obsessions, psychosis and hallucinations were observed in adults. Genotype-TAND correlations showed a higher frequency of self-injury, ASD, academic difficulties and neuropsychological deficits in TSC2. Those with no mutations identified (NMI) showed a mixed pattern of TAND manifestations. Children and those with TSC2 had significantly higher rates of intellectual disability, suggesting that age and genotype comparisons should be interpreted with caution. Conclusions: These results emphasize the magnitude of TAND in TSC and the importance of evaluating for neuropsychiatric comorbidity in all children and adults with TSC, across TSC1 and TSC2 genotypes, as well as in those with no mutations identified. However, the high rates of unreported or missing TAND data in this study underline the fact that, even in expert centres, TAND remains underdiagnosed and potentially undertreated.
Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults with Tuberous Sclerosis Complex: Results from the International TOSCA Study

Anna C. Jansen,Elena Belousova,Mirjana P. Benedik,Tom Carter,Vincent Cottin,Paolo Curatolo,Lisa D'Amato,Guillaume Beaure d'Augeres,Petrus J. de Vries,Jose C. Ferreira,Martha Feucht,Carla Fladrowski,Christoph Hertzberg,Sergiusz Jozwiak,John A. Lawson,Alfons Macaya,Ruben Marques,Rima Nabbout,Finbar O'Callaghan,Jiong Qin,Valentin Sander,Matthias Sauter,Seema Shah,Yukitoshi Takahashi,Renaud Touraine,Sotiris Youroukos,Bernard Zonnenberg,John C. Kingswood,Nobuo Shinohara,Shigeo Horie,Masaya Kubota,Jun Tohyama,Katsumi Imai,Mari Kaneda,Hideo Kaneko,Yasushi Uchida,Tomoko Kirino,Shoichi Endo,Yoshikazu Inoue,Katsuhisa Uruno,Ayse Serdaroglu,Zuhal Yapici,Banu Anlar,Sakir Altunbasak,Olga Lvova,Oleg Valeryevich Belyaev,Oleg Agranovich,Elena Vladislavovna Levitina,Yulia Vladimirovna Maksimova,Antonina Karas,Yuwu Jiang,Liping Zou,Kaifeng Xu,Yushi Zhang,Guoming Luan,Yuqin Zhang,Yi Wang,Meiling Jin,Dingwei Ye,Weiping Liao,Liemin Zhou,Jie Liu,Jianxiang Liao,Bo Yan,Yanchun Deng,Li Jiang,Zhisheng Liu,Shaoping Huang,Hua Li,Kijoong Kim,Pei-Lung Chen,Hsiu-Fen Lee,Jeng-Dau Tsai,Ching-Shiang Chi,Chao-Ching Huang,Kate Riney,Deborah Yates,Patrick Kwan,Surachai Likasitwattanakul,Charcrin Nabangchang,Lunliya Thampratankul Krisnachai Chomtho,Kamornwan Katanyuwong,Somjit Sriudomkajorn,Jo Wilmshurst,Reeval Segel,Tal Gilboa,Michal Tzadok,Aviva Fattal-Valevski,Panagiotis Papathanasopoulos,Antigone Syrigou Papavasiliou,Stylianos Giannakodimos,Stylianos Gatzonis,Evangelos Pavlou,Meropi Tzoufi,A. M. H. Vergeer,Marc Dhooghe,Helene Verhelst,Filip Roelens,Marie Cecile Nassogne,Pierre Defresne,Liesbeth De Waele,Patricia Leroy,Nathalie Demonceau,Benjamin Legros,Patrick Van Bogaert,Berten Ceulemans,Lina Dom,Pierre Castelnau,Anne De Saint Martin,Audrey Riquet,Mathieu Milh,Claude Cances,Jean-Michel Pedespan,Dorothee Ville,Agathe Roubertie,Stephane Auvin,Patrick Berquin,Christian Richelme,Catherine Allaire,Sophie Gueden,Sylvie Nguyen The Tich,Bertrand Godet,Maria Luz Ruiz Falco Rojas,Jaume Campistol Planas,Antonio Martinez Bermejo,Patricia Smeyers Dura,Susana Roldan Aparicio,Maria Jesus Martinez Gonzalez,Javier Lopez Pison,Manuel Oscar Blanco Barca,Eduardo Lopez Laso,Olga Alonso Luengo,Francisco Javier Aguirre Rodriguez,Ignacio Malaga Dieguez,Ana Camacho Salas,Itxaso Marti Carrera,Eduardo Martinez Salcedo,Maria Eugenia Yoldi Petri,Ramon Cancho Candela,Ines da Conceicao Carrilho,Jose Pedro Vieira,Jose Paulo da Silva Oliveira Monteiro,Miguel Jorge Santos de Oliveira Ferreira Leao,Catarina Sofia Marceano Ribeiro Luis,Carla Pires Mendonca,Milda Endziniene,Jurgis Strautmanis,Inga Talvik,Maria Paola Canevini,Antonio Gambardella,Dario Pruna,Salvatore Buono,Elena Fontana,Bernardo Dalla Bernardina,Carmen Burloiu,Iuliu Stefan Bacos Cosma,Mihaela Adela Vintan,Laura Popescu,Karel Zitterbart,Jaroslava Payerova,Ladislav Bratsky,Zuzana Zilinska,Ursula Gruber-Sedlmayr,Matthias Baumann,Edda Haberlandt,Kevin Rostasy,Ekaterina Pataraia,Frances Elmslie,Clare Ann Johnston,Pamela Crawford,Peter Uldall,Maria Dahlin,Paul Uvebrant,Olof Rask,Marit Bjoernvold,Eylert Brodtkorb,Andreas Sloerdahl,Ragnar Solhoff,Martine Sofie Gilje Jaatun,Marek Mandera,Elzbieta Janina Radzikowska,Mariusz Wysocki,Michael Fischereder,Gerhard Kurlemann,Bernd Wilken,Adelheid Wiemer-Kruel,Klemens Budde,Klaus Marquard,Markus Knuf,Andreas Hahn,Hans Hartmann,Andreas Merkenschlager,Regina Trollmann

DOI: https://doi.org/10.3389/fneur.2019.00821

IF: 3.4

2019-01-01

Frontiers in Neurology

Abstract:The onset and growth of subependymal giant cell astrocytoma (SEGA) in tuberous sclerosis complex (TSC) typically occurs in childhood. There is minimal information on SEGA evolution in adults with TSC. Of 2,211 patients enrolled in TOSCA, 220 of the 803 adults (27.4%) ever had a SEGA. Of 186 patients with SEGA still ongoing in adulthood, 153 (82.3%) remained asymptomatic, and 33 (17.7%) were reported to ever have developed symptoms related to SEGA growth. SEGA growth since the previous scan was reported in 39 of the 186 adults (21%) with ongoing SEGA. All but one patient with growing SEGA had mutations in TSC2. Fourteen adults (2.4%) were newly diagnosed with SEGA during follow-up, and majority had mutations in TSC2. Our findings suggest that surveillance for new or growing SEGA is warranted also in adulthood, particularly in patients with mutations in TSC2.
Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome

Jennifer W. Leiding,Tiphanie P. Vogel,Valentine G.J. Santarlas,Rahul Mhaskar,Madison R. Smith,Alexandre Carisey,Alexander Vargas-Hernández,Manuel Silva-Carmona,Maximilian Heeg,Anne Rensing-Ehl,Bénédicte Neven,Jérôme Hadjadj,Sophie Hambleton,Timothy Ronan Leahy,Kornvalee Meesilpavikai,Charlotte Cunningham-Rundles,Cullen M. Dutmer,Svetlana O. Sharapova,Mervi Taskinen,Ignatius Chua,Rosie Hague,Christian Klemann,Larysa Kostyuchenko,Tomohiro Morio,Akaluck Thatayatikom,Ahmet Ozen,Anna Scherbina,Cindy S. Bauer,Sarah E. Flanagan,Eleonora Gambineri,Lisa Giovannini-Chami,Jennifer Heimall,Kathleen E. Sullivan,Eric Allenspach,Neil Romberg,Sean G. Deane,Benjamin T. Prince,Melissa J. Rose,John Bohnsack,Talal Mousallem,Rohith Jesudas,Maria Marluce Dos Santos Vilela,Michael O’Sullivan,Jana Pachlopnik Schmid,Štěpánka Průhová,Adam Klocperk,Matthew Rees,Helen Su,Sami Bahna,Safa Baris,Lisa M. Bartnikas,Amy Chang Berger,Tracy A. Briggs,Shannon Brothers,Vanessa Bundy,Alice Y. Chan,Shanmuganathan Chandrakasan,Mette Christiansen,Theresa Cole,Matthew C. Cook,Mukesh M. Desai,Ute Fischer,David A. Fulcher,Silvanna Gallo,Amelie Gauthier,Andrew R. Gennery,José Gonçalo Marques,Frédéric Gottrand,Bodo Grimbacher,Eyal Grunebaum,Emma Haapaniemi,Sari Hämäläinen,Kaarina Heiskanen,Tarja Heiskanen-Kosma,Hal M. Hoffman,Luis Ignacio Gonzalez-Granado,Anthony L. Guerrerio,Leena Kainulainen,Ashish Kumar,Monica G. Lawrence,Carina Levin,Olaf Neth,Peter Olbrich,Alejandro Palma,Niraj C. Patel,Tamara Pozos,Kahn Preece,Saúl Oswaldo Lugo Reyes,Mark A. Russell,Yael Schejter,Christine Seroogy,Jan Sinclair,Effie Skevofilax,Daniel Suan,Daniel Suez,Paul Szabolcs,Helena Velasco,Klaus Warnatz,Kelly Walkovich,Austen Worth,Svetlana Aleshkevich,Luis M. Allende,T. Prescott Atkinson,Faranaz Atschekzei,Sezin Aydemir,Utku Aygunes,Vincent Barlogis,Ulrich Baumann,John Belko,Liliana Bezrodnik,Ariane Biebl,Lori Broderick,Nancy J. Bunin,Maria Soledad Caldirola,Martin Castelle,Fatih Celmeli,Louis-Marie Charbonnier,Talal A. Chatila,Deepak Chellapandian,Haluk Cokugras,Niall Conlon,Fionnuala Cox,Etienne Crickx,Buket Dalgic,Virgil ASH Dalm,Silvia Danielian,Nerea Dominguez-Pinilla,Tal Dujovny,Mikael Ebbo,Ahmet Eken,Brittany Esty,Alexandre Fabre,Alain Fischer,Mark Hannibal,Laura Huppert,Marc D. Ikeda,Stephen Jolles,Kent W. Jolly,Neil Jones,Maria Kanariou,Elif Karakoc-Aydiner,Theoni Karamantziani,Charikleia Kelaidi,Mary Keogan,Ayşenur Pac Kisaarslan,Ayca Kiykim,Adam Klocperk,Kosmas Kotsonis,Natalia Kuzmenko,Sylvie Leroy,Dimitra Lianou,Hilary Longhurst,Myriam Ricarda Lorenz,Patrick Maffucci,Ania Manson,Sarah Marchal,Marion Malphettes,Lia Furlaneto Marega,Andrea A. Mauracher,Kornvalee Meesilpavikai,Holly Miller,Joy Mombourquette,Noel G. Morgan,Anna Mukhina,Aladjidi Nathalie,Brigitte Nelken,David Nolan,Anna-Carin Norlin,Matias Oleastro,Alper Ozcan,Marlene Pasquet,José Roberto Pegler,Capucine Picard,Sophia Polychronopoulou,Pierre Quartier,Juan Francisco Quesada,Jan Ramakers,Katrina L. Randall,V. Koneti Rao,Allison Remiker,Geraldine Resin,Peter Richmond,Frederic Rieux-Laucat,Yulia Rodina,Pierre Rohrlich,Johnathan Sachs,Inga Sakovich,Christopher Santarlas,Sinan Sari,Gregory Sawicki,Uwe Schauer,Selma C. Scheffler Mendoza,Oksana Schvetz,Reinhold Ernst Schmidt,Klaus Schwarz,Anna Sediva,Kyle Sinclair,Mary Slatter,John Sleasman,Katerina Stergiou,Narissara Suratannon,Kay Tanita,Grace Thompson,Stephen Travis,Timothy Trojan,Maria Tsinti,Ekrem Unal,Luciano Urdinez,Felisa Vazquez-Gomez,Mariana Villa,Michael Weinrich,Mitchell J. Weiss,Benjamin Wright,Ebru Yilmaz,Radana Zachova,Yu Zhang,Mikko R.J. Seppänen,Troy R. Torgerson,Georgios Sogkas,Stephan Ehl,Stuart G. Tangye,Megan A. Cooper,Joshua D. Milner,Lisa R. Forbes Satter,Timi Martelius

DOI: https://doi.org/10.1016/j.jaci.2022.09.002

IF: 14.29

2023-04-01

Journal of Allergy and Clinical Immunology

Abstract:BACKGROUND: In 2014, germline signal transducer and activator of transcription (STAT) 3 gain-of-function (GOF) mutations were first described to cause a novel multisystem disease of early-onset lymphoproliferation and autoimmunity.OBJECTIVE: This pivotal cohort study defines the scope, natural history, treatment, and overall survival of a large global cohort of patients with pathogenic STAT3 GOF variants.METHODS: We identified 191 patients from 33 countries with 72 unique mutations. Inclusion criteria included symptoms of immune dysregulation and a biochemically confirmed germline heterozygous GOF variant in STAT3.RESULTS: Overall survival was 88%, median age at onset of symptoms was 2.3 years, and median age at diagnosis was 12 years. Immune dysregulatory features were present in all patients: lymphoproliferation was the most common manifestation (73%); increased frequencies of double-negative (CD4-CD8-) T cells were found in 83% of patients tested. Autoimmune cytopenias were the second most common clinical manifestation (67%), followed by growth delay, enteropathy, skin disease, pulmonary disease, endocrinopathy, arthritis, autoimmune hepatitis, neurologic disease, vasculopathy, renal disease, and malignancy. Infections were reported in 72% of the cohort. A cellular and humoral immunodeficiency was observed in 37% and 51% of patients, respectively. Clinical symptoms dramatically improved in patients treated with JAK inhibitors, while a variety of other immunomodulatory treatment modalities were less efficacious. Thus far, 23 patients have undergone bone marrow transplantation, with a 62% survival rate.CONCLUSION: STAT3 GOF patients present with a wide array of immune-mediated disease including lymphoproliferation, autoimmune cytopenias, and multisystem autoimmunity. Patient care tends to be siloed, without a clear treatment strategy. Thus, early identification and prompt treatment implementation are lifesaving for STAT3 GOF syndrome.

immunology,allergy
An Entity-Relationship Approach to Modelling Petroleum Engineering Database

S. Al-Fedaghi

Abstract:
Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry

Fabian Beier,Mareike Tometten,Martin Kirschner,Insa Halfmeyer,Margherita Vieri,Kim Kricheldorf,Angela Maurer,Alexander Roeth,Uwe Platzbecker,Markus P. Radsak,Philippe Schafhausen,Selim Corbacioglu,Britta Hoechsmann,C. Matthias Wilk,Claas Hinze,Jörg Chromik,Alexander Egle,Michael Heuser,Michael Kreuter,Ingo Kurth,Steffen Koschmieder,Jens Panse,Robert Meyer,Susanne Isfort,Tim H Brummendorf

DOI: https://doi.org/10.1182/blood-2021-153630

IF: 20.3

2021-11-05

Blood

Abstract:Abstract Introduction: Telomere biology disorders (TBD) are caused by mutations affecting proper telomere maintenance resulting in premature telomere shortening. Telomere length (TL) assessment is currently being used for screening and diagnosis of TBD of which Dyskeratosis congenita (DKC) is the most prominent TBD subtype typically found in children and adolescents. In adults, TBDs are characterized by a broad spectrum of more "cryptic" diverging mono- or oligosymptomatic clinical manifestations such as bone marrow failure (BMF), hepatopathy or interstitial lung disease (ILD). However, despite growing general clinical awareness and exertion of improved TL screening strategies, insufficient data are available about the clinical course of adult, late-onset TBDs. Here, we present a series of 41 consecutive adult TBD cases from 2014 to 2021 identified through the Aachen Telomeropathy registry. Methods and Patients: Median follow-up of the cohort was 2.0 (range 0-6.2) years. In 39/41 patients TBD diagnosis was established based on coexistence of the following three criteria: 1.) Identification of pathogenic variant in a known TBD-related gene via next-generation panel sequencing (NGS) or sequential whole exome sequencing (WES). 2.) The presence of prematurely shortened TL below the 1% percentile (39/41) or 5% percentile (2/41) in the lymphocyte gate detected by flow-FISH and 3.) the presence of BMF or ILD as predominant clinical manifestation. In 2 out of 41 cases, WES did not identify a definitive pathogenic variant. Here, diagnosis of TBD was established due to short telomere below the 1% percentile, BMF and the presence of typical DKC stigmata, other TBD symptoms and a positive family history. Results: Mean age of our cohort was 35.9 ± 17.6 years. 49% (n=20) of patients were females. Results of the genetic screening revealed heterozygous pathogenic variants in TERC (n=14) and TERT (n=11) as the most frequent variants, followed by RTEL1 (n=6), TIN2 (n=1), CTC1 (n=1) and DKC1 (n=1). Homozygous or compound heterozygous pathogenic variants were found for CTC1 (n=2), NHP2 (n=2) or TCAB1 (n=1). 46% (n=19) of patients had a positive family history. BMF was the most frequent symptom with 93% (n=38) presenting with leukopenia, 78% (n=32) with anemia and 76% (n=31) with thrombocytopenia. ILD was suspected/confirmed clinically in 44% (n=18), hepatopathies in 29% (n=12) and cancer in 12% of the patients in past medical history (n=5, liposarcoma, breast cancer, Hodgkin lymphoma, diffuse large B-cell lymphoma, endometrial cancer). Symptoms of the typical DKC triad (leukoplakia, nail dystrophy, abnormal skin pigmentation) were observed in 41% (n=17). Of those, 76% (13/17) presented with only one or two clinical signs. Based on past medical history, the onset of first TBD manifestation was observed at a mean age of 26.9 ± 18.3 years. Time from first symptom observed to the diagnosis of TBD was 8.2 ± 9.5 years. 22% (n=9) patients died during follow-up with mean time of 11.7 ± 10.1 years from first manifestation of TBD to death. Regarding treatment, 39% (n=16) were listed for allogeneic stem cell transplantation (allo Tx), but only 38% (6/16) of these eventually received allo Tx. Immunosuppressive therapy with ATG and CSA was carried out in 12% (n=5) of the patients with no patient responding to treatment. Eltrombopag was given in 5% of cases (n=2) without response. 15% (n=6) received androgen treatment with danazol as the most frequently used drug in five of the six reported cases. All patients showed a response at least in one hematological lineage. Conclusions: Our data support the notion that despite the recent progress in screening and genetic diagnostics, late-onset TBD is still frequently underdiagnosed with several years from first manifestation of disease to diagnosis. Implementation of routine screening for TBD might improve the rate of correct TBD diagnosis and could help to avoid ineffective treatments. Disclosures Beier: Pfizer: Membership on an entity's Board of Directors or advisory committees; Jazz: Other: Travel reembursement; Alexion: Speakers Bureau. Roeth: Novartis: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Kira: Consultancy, Honoraria; Bioverativ, a Sanofi company: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding; Apellis Pharmaceuticals: Consultancy, Honoraria; Alexion Pharmaceuticals Inc.: Consultancy, Honoraria. Platzbecker: AbbVie: Honoraria; Novartis: Honoraria; Celgene/BMS: Honoraria; Janssen: Honoraria; Takeda: Honoraria; Geron: Honoraria. Radsak: Novartis: Consultancy, Honoraria, Other: e.g. travel support; JAZZ: Other: e.g. travel support; Takeda: Consultancy, Honoraria; Celgene/BMS: Consultancy, Honoraria, Other: e.g. travel support; Daiichi Sankyo: Consultancy, Honoraria, Other: e.g. travel support; Astellas: Other: e.g. travel support; Incyte: Consultancy, Honoraria; Corat: Consultancy, Honoraria; Cogent Biosciences: Consultancy, Honoraria; TEVA: Consultancy, Honoraria; Otsuka: Consultancy, Honoraria; Amgen: Other: e.g. travel support; Abbvie: Other: e.g. travel support. Schafhausen: Blueprint Medicines: Membership on an entity's Board of Directors or advisory committees; Alexion: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Swedish Orphan Biovitrum AB: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees. Corbacioglu: Gentium/Jazz Pharmaceuticals: Consultancy, Honoraria. Heuser: AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria; BergenBio: Research Funding; BMS/Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer Pharma AG: Research Funding; Astellas: Research Funding; Karyopharm: Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Tolremo: Membership on an entity's Board of Directors or advisory committees. Koschmieder: Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: (e.g. travel support); Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: (e.g. travel support); Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: (e.g. travel support); Karthos: Other: Travel support; Shire: Honoraria, Other; CTI: Membership on an entity's Board of Directors or advisory committees, Other; Sanofi: Membership on an entity's Board of Directors or advisory committees, Other: Travel support; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding; Geron: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: (e.g. travel support), Research Funding; Alexion: Other: Travel support; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: (e.g. travel support); Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: (e.g. travel support), Research Funding; Ariad: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: (e.g. travel support); Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Baxalta: Membership on an entity's Board of Directors or advisory committees, Other; Abbvie: Other: Travel support; Image Biosciences: Other: Travel support; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding; AOP Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: (e.g. travel support), Research Funding. Panse: Blueprint Medicines: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Chugai: Speakers Bureau; Pfizer: Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Boehringer Ingelheim: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Alexion: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; MSD: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Grunenthal: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Apellis Pharmaceuticals: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Isfort: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel reimbursement; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel reimbursement; Ariad: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria; Hexal: Other: Travel reimbursement; Mundipharma: Other: Travel reimbursement; Amgen: Other: Travel reimbursement; Roche: Other: Travel reimbursement; Alexion: Other: Travel reimbursement. Brummendorf: Bristol Myers: Research Funding; Janssen: Honoraria; Novartis: Honoraria, Patents & Royalties, Research Funding; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Repeat Diagnostics: Research Funding; Takepart Media: Honoraria.

hematology
SOD1 gene screening in ALS – frequency of mutations, patients' attitudes to genetic information and transition to tofersen treatment in a multi-center program

Thomas Meyer Peggy Schumann Torsten Grehl Ute Weyen Susanne Petri Annekathrin Rödiger Robert Steinbach Julian Grosskreutz Sarah Bernsen Patrick Weydt Joachim Wolf René Günther Maximilian Vidovic Petra Baum Moritz Metelmann Jochen H. Weishaupt Berthold Streubel David C. Kasper Yasemin Koc Dagmar Kettemann Jenny Norden Philipp Schmitt Bertram Walter Christoph Münch Susanne Spittel André Maier Péter Körtvélyessy 1 Department of Neurology,Center for ALS and other Motor Neuron Disorders,Charité – Universitätsmedizin Berlin,Corporate Member of Freie Universität Berlin,Humboldt-Universität zu Berlin,and Berlin Institute of Health,Berlin,Germany2 Ambulanzpartner Soziotechnologie APST GmbH,Berlin,Germany3 Department of Neurology,Center for ALS and other Motor Neuron Disorders,Alfried Krupp Krankenhaus,Essen,Germany4 Department of Neurology,Center for ALS and other Motor Neuron Disorders,Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil,Bochum,Germany5 Department of Neurology,Hannover Medical School,Hannover,Germany6 Department of Neurology,Jena University Hospital,Jena,Germany7 ZSE,Zentrum für Seltene Erkrankungen,Jena University Hospital,Jena,Germany8 Department of Neurology,Universitätsmedizin Schleswig-Holstein,Lübeck,Germany9 Department for Neuromuscular Disorders,Bonn University,Bonn,Germany10 DZNE,Deutsches Zentrum für Neurodegenerative Erkrankungen,Bonn,Germany11 Department of Neurology,Diako Mannheim,Mannheim,Germany12 Department of Neurology,Technische Universität Dresden,University Hospital Carl Gustav Carus,Dresden,Germany13 DZNE,Deutsches Zentrum für Neurodegenerative Erkrankungen,Dresden,Germany14 Department of Neurology,University Hospital Leipzig,Leipzig,Germany15 Division for Neurodegenerative Diseases,Neurology Department,University Medicine Mannheim,Heidelberg University,Mannheim Center for Translational Medicine,Mannheim,Germany16 Medical University of Wien,Institute for Pathology,Wien,Austria17 ARCHIMED Life Science GmbH,Wien,Austria

DOI: https://doi.org/10.1080/21678421.2024.2401131

2024-09-14

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Abstract:Objective : To report the frequency of pathogenic SOD1 gene variants in a screening program in amyotrophic lateral sclerosis (ALS), and the clinical practice of transition to an expanded access program (EAP) of tofersen treatment. Methods : From October 2021 to February 2024, at 11 ALS centers in Germany genetic testing for SOD1 , FUS , TARDBP, and C9orf72 was performed. Patients were offered to opt for notification either about all genetic variants or SOD1 variants relevant for tofersen therapy. The transition to the EAP with tofersen was assessed. Results : 1935 patients were screened (94.7% sporadic ALS). 48.8% ( n = 928) opted for notification of treatment-relevant information. Genetic variants were found as follows: SOD1 (likely) pathogenic variants (class 4/5) 1.8% ( n = 34), variants of unknown significance (class 3) 0.8% ( n = 16), FUS (class 4/5) 0.9% ( n = 17) , TARDBP (class 4/5) 1.3% ( n = 25), C9orf72 hexanucleotide repeat expansion 7.0% ( n = 135). In SOD1 -ALS (encompassing class 3–5 variants, n = 50), 68.0% ( n = 34) reported a negative family history. 74.0% ( n = 37) of SOD1 -ALS patients – which represent 1.9% of all participants of the screening program – were transitioned to tofersen. Median duration from start of genetic testing to treatment was 94 days (57 to 295 days). Eight patients declined treatment whereas five individuals died before initiation of therapy. Conclusion : The finding of SOD1 variants in patients with a negative family history underscores the need for a broad genetic screening in ALS. In SOD1 -ALS, the treatment option with tofersen was mostly utilized. The wide range in the transition time to tofersen calls for a SOD1 -ALS management program.

clinical neurology
Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device

Cameron Kirk,Arne Küderle,M. Encarna Micó-Amigo,Tecla Bonci,Anisoara Paraschiv-Ionescu,Martin Ullrich,Abolfazl Soltani,Eran Gazit,Francesca Salis,Lisa Alcock,Kamiar Aminian,Clemens Becker,Stefano Bertuletti,Philip Brown,Ellen Buckley,Alma Cantu,Anne-Elie Carsin,Marco Caruso,Brian Caulfield,Andrea Cereatti,Lorenzo Chiari,Ilaria D'Ascanio,Judith Garcia-Aymerich,Clint Hansen,Jeffrey M. Hausdorff,Hugo Hiden,Emily Hume,Alison Keogh,Felix Kluge,Sarah Koch,Walter Maetzler,Dimitrios Megaritis,Arne Mueller,Martijn Niessen,Luca Palmerini,Lars Schwickert,Kirsty Scott,Basil Sharrack,Henrik Sillén,David Singleton,Beatrix Vereijken,Ioannis Vogiatzis,Alison J. Yarnall,Lynn Rochester,Claudia Mazzà,Bjoern M. Eskofier,Silvia Del Din,Francesca Bottin,Lorenzo Chiari,Cristina Curreli,Ilaria D'Ascanio,Giorgio Davico,Roberta De Michele,Giuliano Galimberti,Luca Palmerini,Saverio Ranciati,Luca Reggi,Marco Viceconti,Lucia D'Apote,Jules Desmond,Megan Doyle,Mary Elliot-Davey,Gilles Gnacadja,Anja Kassner,Beat Knusel,Monika Pocrzepa,Nicolas Pourbaix,Hoi-Shen Radcliffe,Lening Shen,Jennifer Simon,Jesper Havsol,Diana Jarretta,Magnus Jornten-karlsson,Pierre Mugnier,Solange Corriol Rohou,Gabriela Saraiva,Henrik Sillén,Michael Boettger,Igor Knezevic,Frank Kramer,Paolo Piraino,Hubert Trübel,Hajar Ahachad,Hubert Blain,Sylvie Broussous,Francois Canovas,Florent Cerret,Louis Dagneaux,Valerie Driss,Florence Galtier,Charlote Kaan,Stephanie Miot,Eva Murauer,Anne-Sophie Vérissimo,Daniela Berg,Kirsten Emmert,Clint Hansen,Hanna Hildesheim,Jennifer Kudelka,Walter Maetzler,Corina Maetzler,Christian Schlenstedt,Valdo Arnera,Karin Beckstrom,Patrick Folaron,Antonia Gizdic,Fay Horak,Skender Imeri,Stefanie Krieger,Narcis Nica,Natalia Pletneva,Stephen Raymond,Donna Reed,Ara Sekaram,Kristen Sowalsky,Kamiar Aminian,Anisoara Ionescu,Abolfazl Soltani,Bjoern Eskofier,Felix Kluge,Arne Küderle,Martin Ullrich,Victoria Alcaraz Serrano,Magda Bosch de Basea,Joren Buekers,Gabriela Cardenas,Anne-Elie Carsin,Ines Cobo,Anna Delgado Llobet,Laura Delgado Ortiz,Mariona Font Garcia,Judith Garcia Aymerich,Elena Gimeno-Santos,Alicia Jose,Sarah Koch,Ashar Ahmad,Marcel Froehlich,Gilyana Borlikova,Marie-Sidonie Edieux,Ronan Fox,Bill Holt,Kellee Howard,Sean Kelly,Sheila Kelly,Ruth Lalor,Alexandre Malouvier,Kusuma Manavalli Ramanna,Marie Mc Carthy,Gerard Quinn,Isaac Rodriguez Chavez,Peter Schueler,Michal Skackov,Barbara Skerrit,Sara Buttery,Nicholas Hopkinson,Alexis Perkins,Keir Philip,Mike Polkey,Parris Williams,Michael Jackson,David Wenn,Sofie Breuls,Heleen Demeyer,Nitesh Ghosh,Pieter Ginis,Lies Glorie,Valerie Haerens,Lova Hulst,Femke Hulzinga,Wim Janssenns,Alice Nieuwboer,Thierry Troosters,Tim Vanhoutte,Myriam Witvrouw,Marieke Wuyts,Luca Cornelisse,Jordi Evers,Siete Frouws,Neall Mouthaan,Martijn Niessen,Laura Siepman,Aida Aydemir,Yann Hyvert,Martin Aursand Berge,Mara Diaconu,Monika Engdal,Karoline Blix Grønvik,Jorunn Helbostad,Lars Gunnar Johnsen,Anna Marcuzzi,Ingalill Midtsand,Mari Odden,Ingvild Saltvedt,Erika Skaslien,Kristin Taraldsen,Beatrix Vereijken,Ola Bunte,Wim Dartee,Gul Erdemli,Olivier Grenet,Tilo Hache,Sam Hariry,Sabina Hernandez Penna,Felix Kluge,Jacek Lukawy,Suzanne Maahs,Ram Miller,Arne Mueller,Jens Praestgaard,Ronenn Roubenoff,Sandra Schluechter,Leen van Steenbergen,Xuemei Cai,Charmaine Demanuele,Charmaine Demanuele,Mariana Gameiro,Di Junrui,Isik Karahanoglu,Joe Mather,Dimitrios Psaltos,Emma Stokes,Anil Tarachandani,Hao Zhang,Anne-Marie Kirsten,Kirsten Paash,Martina Russ,Henrik Watz,Ines Zimmermann,Clemens Becker,Niki Brenner,Christoph Endress,Martha Gierka,Clarissa Huber,Simon Jaeger,Carl-Philipp Jansen,Bernd Kinner,Jochen Klenk,Elena Litz,Elena Litz,Stefanie Mikolaizak,Kilian Rapp,Matthias Schwab,Lars Schwickert,Erkin Uysal,Martin Wohlrab,Vanessa Zoller,Nadir Ammour,Stephanie Bascle,Fabrice Bonche,Manon Cariou,Matthieu Jouannin,Mike Chambers,Antonella Ciucchiuini,Ariel Dowling,Emilio Merlo-Pich,Max Tolkoff,Lucy Fry,Mark Gordon,Pippa Loupe,Michal Melamed,Michael Reich,Sara Shnider,Marina Brozgol,David Buzaglo,Pablo Cornejo Thumm,Eran Gazit,Nir Giladi,Jeff Hausdorff,Talia Herman,Inbar Hillel,Anat Mirelman,Ayala Saban,Shahar Yehezkyahu,Nikolaos Chynkiamis,Stefano Bertuletti,Marco Caruso,AndreaCereatti,Andrea Manca,Francesca Salis,Valeria Bonanno,Giampaolo Brichetto,Gloria Dalla Costa,Comi Giancarlo,Letizia Leocani,Allia Mahajneh,Matteo Martinis,Mariaemma Rodegher,Andrea Tacchino,Mauro Zaffaroni,Mauro Zaffaroni,Gilbert Buesching,Anja Frei,Katharina Hackl,Melanie Keller,Marion Maggi-Beba,Ashley Polhemus,Milo Puhan,Thomas Riegler,Thomas Sigrist,Sabine Spielmanns,Marc Spielmanns,Valerie Zumbrunnen,Stafanie Dettmer,Heiko Gassner,Teresa Greinwalder,Konstantin Huhn,Jelena Jukic,Jochen Klucken,Franz Marxreiter,Florian Nickel,Martin Regensburger,Veit Rothhammer,Sarah Seifferth,Sabine Stallforth,Tanja Stirnweiß,Andrea Weitzenfelder,Juergen Winkler,Antonio Bevilaqua,Brian Caulfield,Cathy Goulding,Georgiana Ifrim,Tahar Kechadi,Alison Keogh,Brian Mac Namee,Milu Philip,David Singleton,Lisa Alcock,Graham Armitage,Jaume Bacardit,Harry Bailey,Phil Brown,Alma Cantu,Laura Cordova-Rivera,Silvia Del Din,Brook Galna,Ann Gibson,Ashley Hart,Hugo Hiden,Chloe Hinchliffe,Sara Johansson Fernstad,Cameron Kirk,Ellen Lirani-Silva,Encarna Micó Amigo,Isabel Neatrour,Emma Packer,Annette Pantall,Jian Qing Shi,Lynn Rochester,Emily Hume,Dimitrios Megaritis,Ioannis Vogiatzis,Sarah Birchall,Tecla Bonci,Gavin Brittain,Ellen Buckley,Fabio Ciravegna,Sooji Han,Liam Haslam,Neil Ireson,Azza Ishmail,Mahjabin Islam,Vita Lanfranchi,Michael Long,Claudia Mazzà,Jessica McNeil,Shagun Misraq,Sarah Moll,Ahmed Mubarak-Mohamed,Siva Nair,David Paling,Shivani Patel,Dibya Pattanaik,Daisy Priest,Alex Radford,Kirsty Scott,Basil Sharrack,Lubos Vaci,Linda Van Gelder,Mobilise-D consortium,Alma Mater Studiorum - Università di Bologna,Amgen,AstraZeneca AB,Bayer Aktiengesellschaft,Centre Hospitalier Universitaire de Montpellier,Christian-Albrechts-Universität,Clario,Ecole Polytechnique Federale de Lausanne,Friedrich-Alexander-Universitaet Erlangen-Nuernberg,Fundacion Privada Instituto De Salud Global,Gruenenthal GMBH,ICON Clinical Research Limited,Imperial College London,Ixscient Ltd,Katholieke Universiteit Leuven,McRoberts B.V.,Merck KGaA,Norges Teknisk-Naturvitenskapelige Universitet,Novartis Pharma AG,Pfizer Limited,Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH,Robert Bosch Gesellschaft Fur Medizinische Forschung MBH,Sanofi Aventis Recherche et Developpement,Takeda,Teva Pharmaceutical Industries Ltd,The Foundation For Medical Research Infrastructural Development And Health Services,Thorax Foundation,Università degli Studi di Sassari,Università Vita-Salute San Raffaele,Universitat Zurich,Universitatsklinikum Erlangen,University College Dublin,University of Newcastle,University Of Northumbria,University of Sheffield

DOI: https://doi.org/10.1038/s41598-024-51766-5

IF: 4.6

2024-01-21

Scientific Reports

Abstract:This study aimed to validate a wearable device's walking speed estimation pipeline, considering complexity, speed, and walking bout duration. The goal was to provide recommendations on the use of wearable devices for real-world mobility analysis. Participants with Parkinson's Disease, Multiple Sclerosis, Proximal Femoral Fracture, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, and healthy older adults (n = 97) were monitored in the laboratory and the real-world (2.5 h), using a lower back wearable device. Two walking speed estimation pipelines were validated across 4408/1298 (2.5 h/laboratory) detected walking bouts, compared to 4620/1365 bouts detected by a multi-sensor reference system. In the laboratory, the mean absolute error (MAE) and mean relative error (MRE) for walking speed estimation ranged from 0.06 to 0.12 m/s and − 2.1 to 14.4%, with ICCs (Intraclass correlation coefficients) between good (0.79) and excellent (0.91). Real-world MAE ranged from 0.09 to 0.13, MARE from 1.3 to 22.7%, with ICCs indicating moderate (0.57) to good (0.88) agreement. Lower errors were observed for cohorts without major gait impairments, less complex tasks, and longer walking bouts. The analytical pipelines demonstrated moderate to good accuracy in estimating walking speed. Accuracy depended on confounding factors, emphasizing the need for robust technical validation before clinical application.

multidisciplinary sciences
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study

Ana Westenberger,Volha Skrahina,Tatiana Usnich,Christian Beetz,Eva-Juliane Vollstedt,Björn-Hergen Laabs,Jefri J Paul,Filipa Curado,Snezana Skobalj,Hanaa Gaber,Maria Olmedillas,Xenia Bogdanovic,Najim Ameziane,Nathalie Schell,Jan Olav Aasly,Mitra Afshari,Pinky Agarwal,Jason Aldred,Fernando Alonso-Frech,Roderick Anderson,Rui Araújo,David Arkadir,Micol Avenali,Mehmet Balal,Sandra Benizri,Sagari Bette,Perminder Bhatia,Michael Bonello,Pedro Braga-Neto,Sarah Brauneis,Francisco Eduardo Costa Cardoso,Francesco Cavallieri,Joseph Classen,Lisa Cohen,Della Coletta,David Crosiers,Paskal Cullufi,Khashayar Dashtipour,Meltem Demirkiran,Patricia de Carvalho Aguiar,Anna De Rosa,Ruth Djaldetti,Okan Dogu,Maria Gabriela Dos Santos Ghilardi,Carsten Eggers,Bulent Elibol,Aaron Ellenbogen,Sibel Ertan,Giorgio Fabiani,Björn H Falkenburger,Simon Farrow,Tsviya Fay-Karmon,Gerald J Ferencz,Erich Talamoni Fonoff,Yara Dadalti Fragoso,Gençer Genç,Arantza Gorospe,Francisco Grandas,Doreen Gruber,Mark Gudesblatt,Tanya Gurevich,Johann Hagenah,Hasmet A Hanagasi,Sharon Hassin-Baer,Robert A Hauser,Jorge Hernández-Vara,Birgit Herting,Vanessa K Hinson,Elliot Hogg,Michele T Hu,Eduardo Hummelgen,Kelly Hussey,Jon Infante,Stuart H Isaacson,Serge Jauma,Natalia Koleva-Alazeh,Gregor Kuhlenbäumer,Andrea Kühn,Irene Litvan,Lydia López-Manzanares,McKenzie Luxmore,Sujeena Manandhar,Veronique Marcaud,Katerina Markopoulou,Connie Marras,Mark McKenzie,Michele Matarazzo,Marcelo Merello,Brit Mollenhauer,John C Morgan,Stephen Mullin,Thomas Musacchio,Bennett Myers,Anna Negrotti,Anette Nieves,Zeev Nitsan,Nader Oskooilar,Özgür Öztop-Çakmak,Gian Pal,Nicola Pavese,Antonio Percesepe,Tommaso Piccoli,Carolina Pinto de Souza,Tino Prell,Mark Pulera,Jason Raw,Kathrin Reetz,Johnathan Reiner,David Rosenberg,Marta Ruiz-Lopez,Javier Ruiz Martinez,Esther Sammler,Bruno Lopes Santos-Lobato,Rachel Saunders-Pullman,Ilana Schlesinger,Christine M Schofield,Artur F Schumacher-Schuh,Burton Scott,Ángel Sesar,Stuart J Shafer,Ray Sheridan,Monty Silverdale,Rani Sophia,Mariana Spitz,Pantelis Stathis,Fabrizio Stocchi,Michele Tagliati,Yen F Tai,Annelies Terwecoren,Sven Thonke,Lars Tönges,Giulia Toschi,Vitor Tumas,Peter Paul Urban,Laura Vacca,Wim Vandenberghe,Enza Maria Valente,Franco Valzania,Lydia Vela-Desojo,Caroline Weill,David Weise,Joanne Wojcieszek,Martin Wolz,Gilad Yahalom,Gul Yalcin-Cakmakli,Simone Zittel,Yair Zlotnik,Krishna K Kandaswamy,Alexander Balck,Henrike Hanssen,Max Borsche,Lara M Lange,Ilona Csoti,Katja Lohmann,Meike Kasten,Norbert Brüggemann,Arndt Rolfs,Christine Klein,Peter Bauer

DOI: https://doi.org/10.1093/brain/awae188

IF: 14.5

2024-08-01

Brain

Abstract:Estimates of the spectrum and frequency of pathogenic variants in Parkinson's disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has reached the clinical trial stage, a major obstacle in conducting these trials is that PD patients are largely unaware of their genetic status and, therefore, cannot be recruited. Expanding the number of investigated PD-related genes and including genes related to disorders with overlapping clinical features in large, well-phenotyped PD patient groups is a prerequisite for capturing the full variant spectrum underlying PD and for stratifying and prioritizing patients for gene-targeted clinical trials. The Rostock Parkinson's disease (ROPAD) study is an observational clinical study aiming to determine the frequency and spectrum of genetic variants contributing to PD in a large international cohort. We investigated variants in 50 genes with either an established relevance for PD or possible phenotypic overlap in a group of 12 580 PD patients from 16 countries [62.3% male; 92.0% White; 27.0% positive family history (FH+), median age at onset (AAO) 59 years] using a next-generation sequencing panel. Altogether, in 1864 (14.8%) ROPAD participants (58.1% male; 91.0% White, 35.5% FH+, median AAO 55 years), a PD-relevant genetic test (PDGT) was positive based on GBA1 risk variants (10.4%) or pathogenic/likely pathogenic variants in LRRK2 (2.9%), PRKN (0.9%), SNCA (0.2%) or PINK1 (0.1%) or a combination of two genetic findings in two genes (∼0.2%). Of note, the adjusted positive PDGT fraction, i.e. the fraction of positive PDGTs per country weighted by the fraction of the population of the world that they represent, was 14.5%. Positive PDGTs were identified in 19.9% of patients with an AAO ≤ 50 years, in 19.5% of patients with FH+ and in 26.9% with an AAO ≤ 50 years and FH+. In comparison to the idiopathic PD group (6846 patients with benign variants), the positive PDGT group had a significantly lower AAO (4 years, P = 9 × 10-34). The probability of a positive PDGT decreased by 3% with every additional AAO year (P = 1 × 10-35). Female patients were 22% more likely to have a positive PDGT (P = 3 × 10-4), and for individuals with FH+ this likelihood was 55% higher (P = 1 × 10-14). About 0.8% of the ROPAD participants had positive genetic testing findings in parkinsonism-, dystonia/dyskinesia- or dementia-related genes. In the emerging era of gene-targeted PD clinical trials, our finding that ∼15% of patients harbour potentially actionable genetic variants offers an important prospect to affected individuals and their families and underlines the need for genetic testing in PD patients. Thus, the insights from the ROPAD study allow for data-driven, differential genetic counselling across the spectrum of different AAOs and family histories and promote a possible policy change in the application of genetic testing as a routine part of patient evaluation and care in PD.
Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype

Petrus J. de Vries,Elena Belousova,Mirjana P. Benedik,Tom Carter,Vincent Cottin,Paolo Curatolo,Maria Dahlin,Lisa D'Amato,Guillaume Beaure d'Augères,José C. Ferreira,Martha Feucht,Carla Fladrowski,Christoph Hertzberg,Sergiusz Jozwiak,John A. Lawson,Alfons Macaya,Ruben Marques,Rima Nabbout,Finbar O'Callaghan,Jiong Qin,Valentin Sander,Matthias Sauter,Seema Shah,Yukitoshi Takahashi,Renaud Touraine,Sotiris Youroukos,Bernard Zonnenberg,John C. Kingswood,Anna C. Jansen,TOSCA Investigators,Nobuo Shinohara,Shigeo Horie,Masaya Kubota,Jun Tohyama,Katsumi Imai,Mari Kaneda,Hideo Kaneko,Yasushi Uchida,Tomoko Kirino,Shoichi Endo,Yoshikazu Inoue,Katsuhisa Uruno,Ayse Serdaroglu,Zuhal Yapici,Banu Anlar,Sakir Altunbasak,Olga Lvova,Oleg Valeryevich Belyaev,Oleg Agranovich,Elena Vladislavovna Levitina,Yulia Vladimirovna Maksimova,Antonina Karas,Yuwu Jiang,Liping Zou,Kaifeng Xu,Yushi Zhang,Guoming Luan,Yuqin Zhang,Yi Wang,Meiling Jin,Dingwei Ye,Weiping Liao,Liemin Zhou,Jie Liu,Jianxiang Liao,Bo Yan,Yanchun Deng,Li Jiang,Zhisheng Liu,Shaoping Huang,Hua Li,Kijoong Kim,Pei-Lung Chen,Hsiu-Fen Lee,Jeng-Dau Tsai,Ching-Shiang Chi,Chao-Ching Huang,Kate Riney,Deborah Yates,Patrick Kwan,Surachai Likasitwattanakul,Charcrin Nabangchang,Lunliya Thampratankul Krisnachai Chomtho,Kamornwan Katanyuwong,Somjit Sriudomkajorn,Jo Wilmshurst,Reeval Segel,Tal Gilboa,Michal Tzadok,Aviva Fattal-Valevski,Panagiotis Papathanasopoulos,Antigone Syrigou Papavasiliou,Stylianos Giannakodimos,Stylianos Gatzonis,Evangelos Pavlou,Meropi Tzoufi,A. M. H. Vergeer,Marc Dhooghe,Hélène Verhelst,Filip Roelens,Marie Cecile Nassogne,Pierre Defresne,Liesbeth De Waele,Patricia Leroy,Nathalie Demonceau,Benjamin Legros,Patrick Van Bogaert,Berten Ceulemans,Lina Dom,Pierre Castelnau,Anne De Saint Martin,Audrey Riquet,Mathieu Milh,Claude Cances,Jean-Michel Pedespan,Dorothee Ville,Agathe Roubertie,Stéphane Auvin,Patrick Berquin,Christian Richelme,Catherine Allaire,Sophie Gueden,Sylvie Nguyen The Tich,Bertrand Godet,Maria Luz Ruiz Falco Rojas,Jaume Campistol Planas,Antonio Martinez Bermejo,Patricia Smeyers Dura,Susana Roldan Aparicio,Maria Jesus Martinez Gonzalez,Javier Lopez Pison,Manuel Oscar Blanco Barca,Eduardo Lopez Laso,Olga Alonso Luengo,Francisco Javier Aguirre Rodriguez,Ignacio Malaga Dieguez,Ana Camacho Salas,Itxaso Marti Carrera,Eduardo Martinez Salcedo,Maria Eugenia Yoldi Petri,Ramon Cancho Candela,Ines da Conceicao Carrilho,Jose Pedro Vieira,José Paulo da Silva Oliveira Monteiro,Miguel Jorge Santos de Oliveira Ferreira Leao,Catarina Sofia Marceano Ribeiro Luis,Carla Pires Mendonca,Milda Endziniene,Jurgis Strautmanis,Inga Talvik,Maria Paola Canevini,Antonio Gambardella,Dario Pruna,Salvatore Buono,Elena Fontana,Bernardo Dalla Bernardina,Carmen Burloiu,Iuliu Stefan Bacos Cosma,Mihaela Adela Vintan,Laura Popescu,Karel Zitterbart,Jaroslava Payerova,Ladislav Bratsky,Zuzana Zilinska,Ursula Gruber-Sedlmayr,Matthias Baumann,Edda Haberlandt,Kevin Rostasy,Ekaterina Pataraia,Frances Elmslie,Clare Ann Johnston,Pamela Crawford,Peter Uldall,Paul Uvebrant,Olof Rask,Marit Bjoernvold,Eylert Brodtkorb,Andreas Sloerdahl,Ragnar Solhoff,Martine Sofie Gilje Jaatun,Marek Mandera,Elzbieta Janina Radzikowska,Mariusz Wysocki,Michael Fischereder,Gerhard Kurlemann,Bernd Wilken,Adelheid Wiemer-Kruel,Klemens Budde,Klaus Marquard,Markus Knuf,Andreas Hahn,Hans Hartmann,Andreas Merkenschlager,Regina Trollmann

DOI: https://doi.org/10.3389/fneur.2020.00603

IF: 3.4

2020-07-08

Frontiers in Neurology

Abstract:Background: Knowledge is increasing about TSC-Associated Neuropsychiatric Disorders (TAND), but little is known about the potentially confounding effects of intellectual ability (IA) on the rates of TAND across age, sex, and genotype. We evaluated TAND in (a) children vs. adults, (b) males vs. females, and (c) TSC1 vs. TSC2 mutations, after stratification for levels of IA, in a large, international cohort. Methods: Individuals of any age with a documented visit for TSC in the 12 months prior to enrolment were included. Frequency and percentages of baseline TAND manifestations were presented by categories of IA (no intellectual disability [ID, intelligence quotient (IQ)>70]; mild ID [IQ 50–70]; moderate-to-profound ID [IQ<50]). Chi-square tests were used to test associations between ID and TAND manifestations. The association between TAND and age (children vs. adults), sex (male vs. female), and genotype ( TSC1 vs. TSC2 ) stratified by IA levels were examined using the Cochran–Mantel–Haenszel tests. Results: Eight hundred and ninety four of the 2,211 participants had formal IQ assessments. There was a significant association ( P < 0.05) between levels of IA and the majority of TAND manifestations, except impulsivity ( P = 0.12), overactivity ( P = 0.26), mood swings ( P = 0.08), hallucinations ( P = 0.20), psychosis ( P = 0.06), depressive disorder ( P = 0.23), and anxiety disorder ( P = 0.65). Once controlled for IA, children had higher rates of overactivity, but most behavioral difficulties were higher in adults. At the psychiatric level, attention deficit hyperactivity disorder (ADHD) was seen at higher rates in children while anxiety and depressive disorders were observed at higher rates in adults. Compared to females, males showed significantly higher rates of impulsivity and overactivity, as well as autism spectrum disorder (ASD) and ADHD. No significant age or sex differences were observed for academic difficulties or neuropsychological deficits. After controlling for IA no genotype-TAND associations were observed, except for higher rates of self-injury in individuals with TSC2 mutations. Conclusions: Findings suggest IA as risk marker for most TAND manifestations. We provide the first evidence of male preponderance of ASD and ADHD in individuals with TSC. The study also confirms the association between TSC2 and IA but, once controlling for IA, disproves the previously reported TSC2 association with ASD and with most other TAND manifestations.

neurosciences,clinical neurology

Anonymity in Attribute-Based Group Signatures

Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy

Treatment Patterns and Use of Resources in Patients with Tuberous Sclerosis Complex: Insights from the TOSCA Registry

Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism-the Find-AF 2 study-rationale and design

Epidemiology of 7375 children and adolescents hospitalized with COVID-19 in Germany, reported via a prospective, nationwide surveillance study in 2020–2022

5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2

[Laryngeal receptors in the expiratory reflex].

Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project)

The German National Registry of Primary Immunodeficiencies (2012-2017)

Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex.

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT

Postoperative Complications and Mobilization Following Major Abdominal Surgery With Versus Without Fitness Tracker-based Feedback (EXPELLIARMUS): A Student-led Multicenter Randomized Controlled Clinical Trial of the CHIR-Net SIGMA Study Group

TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study

Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults with Tuberous Sclerosis Complex: Results from the International TOSCA Study

Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome

An Entity-Relationship Approach to Modelling Petroleum Engineering Database

Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry

SOD1 gene screening in ALS – frequency of mutations, patients' attitudes to genetic information and transition to tofersen treatment in a multi-center program

Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device

Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study

Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype